Drug Resistance Updates Fighting bacterial infections—Future treatment options Jenny Fernebro 夽

Transcription

Drug Resistance Updates 14 (2011) 125–139
Contents lists available at ScienceDirect
Drug Resistance Updates
journal homepage: www.elsevier.com/locate/drup
Fighting bacterial infections—Future treatment options夽
Jenny Fernebro ∗
Swedish Research Council, Vetenskapsrådet, Klarabergsviadukten 82, Box 1035, 101 38 Stockholm, Sweden
a r t i c l e
i n f o
Article history:
Received 18 January 2011
Received in revised form 31 January 2011
Accepted 31 January 2011
Keywords:
Antibiotics
Resistance
Antimicrobial peptide
Antivirulence
Bacteriophage
Beta-lactamase inhibitor
Efflux pump inhibitor
Therapeutic antibody
Vaccine
a b s t r a c t
This review summarizes ongoing research aimed at finding novel drugs as alternatives to traditional
antibiotics. Anti-virulence approaches, phage therapy and therapeutic antibodies are strategies that may
yield drugs with high specificity and narrow spectra. Several candidates are currently being evaluated in
clinical trials, mostly for topical applications, but so far, none have been approved for market authorization. Candidates based on antimicrobial peptides (natural, semisynthetic and synthetic) are also
being tested in clinical trials, mostly for the topical treatment of chronic infections. An alternative to
the development of new antibiotics is to find potentiators of traditional antibiotics; in this respect, betalactamase inhibitors are already in clinical use. Novel variants are under investigation as well as efflux
pump inhibitors.
© 2011 Elsevier Ltd. All rights reserved.
1. Introduction
Because of the development of antibiotic resistance in virtually all clinically important pathogens, alternatives to conventional
antibiotics are urgently needed. The majority of the antibiotics used
today originate from Actinomycetales, mostly Streptomyces, and
were isolated during the “golden age” of antibiotics discovery, the
period from the 1940s to the 1970s. Natural products have proven
to be highly efficient for the treatment of bacterial infections and,
not surprisingly, the variety of drugs based on natural products
is enormous. There are drugs with broad and narrow spectra for
oral, topical or parenteral administration and with activities against
almost all known pathogens. Most natural product-based candidates currently under development are new, improved versions of
old drugs, exemplified by the recently FDA-approved glycopeptide
telavancin (Guskey and Tsuji, 2010). The chemical modification of
existing drugs has proven to be the most efficient way to develop
novel drugs active against resistant strains. However, these new
agents are doomed to suffer from resistance development as well.
Therefore, the development of antibacterial drugs with completely
new modes of action is much needed. In 1995, the complete genome
of Haemophilus influenzae was published, marking the beginning of
夽 From the ReAct Conference “The Global Need for Effective Antibiotics—Moving
Toward Concerted Action, ReAct”, Uppsala University, Uppsala, Sweden, 2010.
∗ Tel.: +46 8 546 44 132; fax: +46 8 546 44 180.
E-mail address: jenny.fernebro@vr.se
1368-7646/$ – see front matter © 2011 Elsevier Ltd. All rights reserved.
doi:10.1016/j.drup.2011.02.001
the genomic era. Hopes were high that novel targets would be identified, leading to new drug candidates. The results, however, have
been poor. Employees at GlaxoSmithKline published a review in
2007 summarizing the efforts made by the company in target-based
drug research (Payne et al., 2007). Seventy screenings of libraries
containing between 260,000 and 530,000 molecules resulted in
five candidates, none of which have subsequently passed clinical trials to become licensed. The study reveals the complexity
in finding novel antibacterial drugs. Still, alternatives to conventional antibiotics are needed; research to find those alternatives is
ongoing. This report attempts to review the efforts made within
seven fields: antimicrobial peptides (AMPs), antivirulence strategies, phage therapy, therapeutic antibodies, vaccines, potentiators
of currently used antibiotics and antibacterial biomaterials. Characteristics of antibacterial drugs that may result from these research
fields can be found in Table 1.
2. Antimicrobial peptides
2.1. Background
Antimicrobial peptides (AMPs), which are present in all animals,
are evolutionary conserved components of the innate immune
defense (Zasloff, 2002). Eukaryotic AMPs are small (10–50 amino
acids), cationic and contain both hydrophobic and hydrophilic parts
(Hancock and Sahl, 2006). Traditionally, they have been described
as “antimicrobial”, with most having the ability to disrupt bacterial
membranes, killing the bacteria. The exact mechanism of action is
126
J. Fernebro / Drug Resistance Updates 14 (2011) 125–139
Table 1
Characteristics of antibacterial drugs that may result from different research strategies.
Risk of resistance
development
Spectrum of
specificity
Spectrum of potential
target bacteria
Routes of
administration
Antivirulence strategies
Antimicrobial peptides
Bacteriophages/lysins
Low
Low
High/low
Narrow
Broad
Narrow
Broad
Broad
Broad
Therapeutic antibodies
Vaccines
Low
Low
Narrow
Narrow
Broad
Broad
Potentiators
High
Broad
Antibacterial biomaterials
Uncertain
Broad and
narrow
Broad
Mainly topical
Mainly topical
Topical and
systemic
Systemic
Mainly
systemic
Topical and
systemic
–
unknown. It has recently been discovered that some AMPs are not
directly bactericidal, but rather exert their effects by immunomodulation (Bowdish et al., 2005). Generally, AMPs are broad-spectrum
antibiotics active against not only bacteria but also certain viruses
and fungi. At higher concentrations, many may exhibit toxicity to
eukaryotic cells. Magainins, which are AMPs from frogs, are among
the best-studied AMPs (Berkowitz et al., 1990). AMPs of prokaryotic origin are called “bacteriocins” and often have a narrower
spectrum (Riley and Wertz, 2002). Nisin, a bacteriocin, is the commercially most important AMP. It has been used extensively for
food preservation (Riley and Wertz, 2002). The polymyxins, bacterial lipopeptides, were introduced into the clinic in the 1960s,
but owing to their toxicity, they were replaced by other antibiotics
(Falagas and Kasiakou, 2005). They are now commonly used only
in topical therapy and considered a last-resort treatment of severe
infections caused by multidrug resistant Gram-negatives such as
Pseudomonas aeruginosa and Acinetobacter baumannii.
2.2. Clinical potential
The broad-spectrum activity and rapid mode of action of AMPs
make them promising drug candidates. The level of induced resistance against AMPs is also anticipated to be low (Zasloff, 2002).
Most AMPs in preclinical and clinical trials today have been developed for topical applications (Hancock and Sahl, 2006). Examples
of indications are catheter site infections, cystic fibrosis, acne and
wound healing. The development of AMPs into drugs, however, has
encountered several difficulties. Not only may some AMPs be toxic
but also the production cost for synthetic peptides is high and their
in vivo stability, especially toward proteases, is an issue (Hancock
and Sahl, 2006). A theoretical concern for the pharmacological use
of AMPs closely related to human ones is that selection for bacterial
resistance could generate organisms of higher virulence potential.
The fact that AMP function does not depend on specific amino acid
sequences, but rather on biochemical properties, has opened the
opportunity to develop synthetic peptide mimics for therapeutic
use.
2.3. Ongoing research
Two AMPs (omiganan and pexiganan) have shown efficacy
in Phase III clinical trials, but neither of them has been
approved for clinical use (Hancock and Sahl, 2006). Pexiganan,
a synthetic analogue to the magainins, was developed for the
topical treatment of diabetic foot ulcers, whereas omiganan was
investigated for the prevention of catheter-related infections.
Development programs for these two drug candidates are still running (www.dipexiumpharmaceuticals.com, www.migenix.com).
Several synthetic peptide mimics have shown efficacy in animal
models (Choi et al., 2009; Livne et al., 2009; Radzishevsky et al.,
2007; Rotem et al., 2008; Sarig et al., 2010). Oligomers of acylated lysines (OAKs) (Livne et al., 2009; Radzishevsky et al., 2007;
Broad
Rotem et al., 2008; Sarig et al., 2010), arylamide foldamers (Choi
et al., 2009) and lipohexapeptides (Zhang and Falla, 2010) are
all classes of broad-spectrum peptide mimetics that have been
used successfully in vivo. Moreover, candidates from the groups
of OAKs and arylamide foldamers have shown efficacy against
staphylococcal infection in mice when delivered systemically (Choi
et al., 2009; Livne et al., 2009; Sarig et al., 2010). Some synthetic
peptide mimics are also in clinical trials. Promising results were
recently reported from a Phase Ib trial of the intravenously delivered defensin-mimetic PMX-30063, active against Staphylococcus
spp. Phase II trials for skin and soft tissue infections are underway
(www.polymedix.com). LTX-109, a broad-spectrum synthetic peptidomimetic, is currently being evaluated for nasal decolonization
of MRSA in a Phase I/IIa trial (www.lytixbiopharma.com). Peptides that are more closely related to endogenous ones are also
being investigated. The human-derived peptide DPK-060 has successfully gone through Phase I/IIa clinical trials for topical use
against atopic dermatitis (www.dermagen.se, Schmidtchen et al.,
2009). Two other investigational drugs (drugs under study but
not yet approved for clinical use), hLF1-11 and talactoferrin, both
based on human lactoferrin, have been tested in clinical trials
(Velden et al., 2009, www.agennix.com). These peptides appear
to have both immunomodulatory and antibacterial properties.
Talactoferrin has been shown to stimulate wound healing and was
recently evaluated as oral therapy against severe sepsis in a Phase II
trial with promising results (www.agennix.com, Engelmayer et al.,
2008). Prophylactic oral administration of bovine lactoferrin has
been reported to reduce the incidence of early onset sepsis in
very-low birth weight premature infants (Manzoni et al., 2009).
IMX942, another peptide-based candidate with immunomodulatory properties, has shown efficacy in animal studies and recently
went through a Phase I clinical trial (delivered intravenously)
(www.inimexpharma.com, Scott et al., 2007). A lantibiotic (bacterial AMP), NAI-107, is also under preclinical development (Jabes and
Donadio, 2010). Finally, the first fungal AMP, plectasin, was identified a few years ago (Mygind et al., 2005). It is highly effective
against Streptococcus pneumoniae, non-toxic to eukaryotic cells,
stable, has the potential for systemic delivery and can be produced by recombinant expression (Mygind et al., 2005). Promising
preclinical data have recently been published on plectasin and an
optimized, more broad-spectrum version of it, NZ2114 (Andes et al.,
2009; Ostergaard et al., 2009; Brinch et al., 2010). The mode of
action of these peptides, targeting the bacterial cell wall precursor
Lipid II, has also been elucidated (Schneider et al., 2010).
3. Antivirulence strategies
3.1. Background
Most traditionally used antibiotics kill bacteria by interfering
with essential cellular processes. An alternative to this approach
is to disarm the pathogens, making it easier for the host innate
immune system to clear the infection. Virulence is defined as the
ability of a pathogen to cause disease. Some of the major targets
of antivirulence research are toxins, quorum-sensing, biofilm production, type III secretion and adhesion. Toxins are produced by
numerous pathogenic bacteria and in many cases the immune
defense can manage the infection well if the toxins are taken
out of the equation. A large number of Gram-negative bacteria
release their toxins by type III secretion, making the machinery
used in this process another potential target. Type III secretion
involves the formation of a needle-like structure that delivers toxins and other effector molecules directly into host cells (Galan and
Wolf-Watz, 2006). Quorum-sensing – another potential target –
can be described as the process by which bacteria “talk” to each
other. Bacteria can sense each other by taking up small molecules
secreted by other bacteria nearby; in this way, bacteria can act
as a population instead of as individuals (Kaufmann et al., 2008).
Quorum-sensing enables bacteria to form biofilms, an effective
approach to becoming more resistant toward both antibiotics and
host immune responses. Finally, host cell adhesion is a critical initial step in bacterial colonization and thus a promising target for
antibacterial drugs.
Targeting bacterial virulence is attractive since it is specific
toward pathogenic bacteria and spares the commensal flora. Since
bacterial viability is not directly targeted, it is also unlikely that
inhibitors of virulence would show cross-resistance with existing
antibiotics or even evoke novel modes of resistance. Antivirulence
drugs could be used both systemically and locally. The indications
would vary depending on the specific virulence mechanism targeted. One application could be prophylactic use under certain
circumstances, such as travelling, a bioterrorism threat or during
an epidemic. Developing drugs based on antivirulence has several
issues that need to be addressed. The evaluation of new drugs relies
on robust in vitro assays for pharmacological studies. Since many
antivirulence drugs do not have a phenotypic effect that can be
assayed in vitro, novel assays must be set up that mimic the in vivo
setting. Others, such as inhibitors of toxins, may be easier to monitor. The narrow specificity of virulence inhibitors requires rapid,
precise diagnostic methods, as well as novel assays for susceptibility testing.
The development of anti-toxin antibodies is the antivirulence
strategy that is closest to clinical application (described below in
the section about therapeutic antibodies). Several other alternatives, however, are under investigation (Table 2). Because of the
bioterrorism threat, inhibitors of anthrax toxins have been identified (Laine et al., 2010; Min et al., 2004; Tonello et al., 2002;
Karginov et al., 2005; Moayeri et al., 2006; Mourez et al., 2001;
Shoop et al., 2005; Xiong et al., 2006; Panchal et al., 2004; Turk
et al., 2004), with several of these having shown potency in animal models (Karginov et al., 2005; Moayeri et al., 2006; Mourez
et al., 2001; Shoop et al., 2005; Xiong et al., 2006). At least one
is under commercial preclinical development (Xiong et al., 2006).
Inhibition of toxins produced by Clostridium botulinum (Boldt et al.,
2006; Burnett et al., 2003; Eubanks et al., 2007; Li et al., 2010; Pang
et al., 2010; Roxas-Duncan et al., 2009; Schmidt and Stafford, 2002;
Silhar et al., 2010), P. aeruginosa (Arnoldo et al., 2008), Shiga toxinproducing Escherichia coli (Armstrong et al., 1991; Kitov et al., 2008;
Nishikawa et al., 2002; Paton et al., 2000; Watanabe-Takahashi
et al., 2010; Kitov et al., 2000), Staphylococcus aureus (Ragle et al.,
2010) and Vibrio cholerae (Hung et al., 2005) has also been reported.
127
The mode of action of these inhibitors includes direct binding to
the toxin, binding to the toxin receptor and manipulation of gene
expression. One of these toxin inhibitors, Synsorb-Pk, was tested
in clinical trials, but failed to show efficacy (to my knowledge
the only non-antibody virulence inhibitor tested in clinical trials)
(Trachtman et al., 2003). An elegant example of toxin inhibition
is the use of a cholesterol biosynthesis inhibitor to block staphylococcal virulence (Liu et al., 2008). Similarities between crystal
structures in human and bacterial biosynthetic pathways led the
researchers to screen squalene synthase inhibitors for activity
toward staphylococci, resulting in the identification of an inhibitor
with potency in vivo. Several studies have identified type III secretion inhibitors active against important Gram-negatives such as
Yersinia, E. coli, Chlamydia, Shigella, Pseudomonas and Salmonella
(Aiello et al., 2010; Felise et al., 2008; Gauthier et al., 2005; Hudson
et al., 2007; Kauppi et al., 2003; Larzabal et al., 2010; Muschiol et al.,
2006; Negrea et al., 2007; Pan et al., 2009; Veenendaal et al., 2009;
Wolf et al., 2006). Many of these inhibitors are effective toward
more than one bacterial species and some are currently being
investigated for commercial development (www.microbiotix.com,
www.creativeantibiotics.com). In the search for inhibitors of adhesion, a group of compounds designated pilicides has been identified.
These compounds inhibit E. coli pilus synthesis, thereby making
the bacteria less adhesive (Pinkner et al., 2006; Svensson et al.,
2001). Recently, modifications of a pilicide were shown to render
it effective toward curli production as well, enhancing its antiadhesive properties (Cegelski et al., 2009). Many companies and
researchers are also investigating methods to prevent biofilm formation. RNAIII-inhibiting peptide (RIP) targets quorum sensing in
S. aureus and has been shown to prevent biofilm formation in vivo
(Balaban et al., 1998; Giacometti et al., 2003). Furanone-based compounds (Hentzer et al., 2003) and acyl-homoserine lactones (Geske
et al., 2005) have been shown to prevent Pseudomonas biofilm formation via quorum sensing inhibition. Recently, novel inhibitors
for quorum sensing in E. coli and V. cholerae were also identified
(Gutierrez et al., 2009). Other targets for antivirulence drugs are
Gram-positive sortases (Chenna et al., 2010; Kudryavtsev et al.,
2009; Maresso et al., 2007; Oh et al., 2004; Suree et al., 2009),
the heptose biosynthesis in Gram-negatives (De Leon et al., 2006;
Desroy et al., 2009; Moreau et al., 2008), FimH in E. coli (Larsson
et al., 2005; Wellens et al., 2008) and iron acquisition systems
(Banin et al., 2008; Ferreras et al., 2005; Kaneko et al., 2007). Some
of these are under commercial development (Desroy et al., 2009;
Moreau et al., 2008). Furthermore, an inhibitor of QseC signaling,
LED209, was recently discovered (Rasko et al., 2008). QseC is a sensor histidine kinase required for regulation of virulence factors in
many important Gram-negatives. LED209 was shown to attenuate
virulence in a mouse model of Salmonella infection.
4. Bacteriophages and lysins
4.1. Background
Bacteriophages (phages) are bacteria-specific viruses present in
nearly all environmental niches. Most known phages are “lytic”
phages, which ultimately lyse and kill the host bacterial cells to
release their progeny (O’flaherty et al., 2009). Other phages are
“lysogenic” and do not kill the host, being incorporated into the
bacterial genome as prophages and only attack and lyse the host
organism on rare events (O’flaherty et al., 2009). Phage therapy,
investigated worldwide during the first half of the 20th century,
has a long and controversial history. It was abandoned by the
Western world after the introduction of antibiotics, but continued to be used in the former Soviet Union. The Eliava Institute
in Georgia, which has treated thousands of people for almost a
128
Table 2
Examples of inhibitors of virulence that have shown efficacy in animal models.
Target
Inhibitor
Mode of action
Adhesion
Pilicides/curlicides (Cegelski et al., 2009)
Inhibit E. coli pilus and/or curli assembly
Biofilm production/Quorum-sensing
RNAIII-inhibiting peptide (Balaban et al., 1998)
Furanone derivates (Hentzer et al., 2003)
Inhibits S. aureus quorum sensing
Inhibit P. aeruginosa quorum sensing
Toxins
Hydroxamate lethal factor inhibitor (Shoop
et al., 2005)
Cisplatin (Moayeri et al., 2006)
Polyvalent inhibitors of anthrax toxin (Mourez
et al., 2001)
␤-cyclodextrin derivatives (Karginov et al.,
2005)
BPH-652 (Liu et al., 2008)
Ac-PPP-tet (Watanabe-Takahashi et al., 2010)
Inhibits B. anthracis lethal factor protease activity
Inhibits B. anthracis protective antigen
Inhibit B. anthracis toxin assembly
Block the B. anthracis protective antigen pore
Inhibits S. aureus production of staphyloxanthin
Alters the intracellular transport of E. coli Stx2
Type III secretion
INP0007 and INP0403 (Hudson et al., 2007)
Block type III secretion in Y. pestis and Salmonella
enterica serovar Typhimurium
Virulence gene regulation
LED209 (Rasko et al., 2008)
Inhibits QseC signaling in several Gram-negative
pathogens
Inhibits V. cholera production of cholera toxin and the
toxin coregulated pilus
Virstatin (Hung et al., 2005)
century, is an example of an institute entirely devoted to phage
research and phage therapy (Kutateladze and Adamia, 2008). However, the documentation of these clinical applications has been
poor and much has been published in Russian. The food industry
is another potential area of use for phages. In 2006, the US Food
and Drug Administration (FDA) approved the use of bacteriophages
in the prevention of Listeria monocytogenes contamination of meat
and poultry (www.intralytix.com).
Because phages are the natural predators of bacteria, using
them as antibiotics may seem quite straightforward. Properties
that make phages good drug candidates are that they are cheap
to produce and very specific (Hanlon, 2007). However, the risk of
resistance development is high and there may be clinical problems
with neutralization of phages by the host immune response (Merril
et al., 2003). Theoretically, the safety profile of phages should be
excellent because of their specific action; however, little formal
clinical data are available. Another major concern is the lack of data
regarding efficacy and pharmacokinetics. Phages have very narrow
specificity and thus phage therapy will require good diagnostics
to identify precisely the infecting agent. The indications for phage
therapy currently being evaluated include topical use on wound
infections caused by, for example, P. aeruginosa or S. aureus, as
well as other chronic infections, such as P. aeruginosa infection in
cystic fibrosis patients. Another potential area of use is oral treatment for enteric infections. It may also be possible to use phages
in a prophylactic fashion as decolonizers, eradicating the nasopharyngeal carriage of, for example, S. aureus in high-risk groups. An
alternative to using whole phage particles is to use phage lysins.
These are highly potent enzymes degrading the bacterial cell wall
(Fischetti, 2010). Resistance development toward lysins has not yet
been reported (Fischetti, 2010).
In recent years a handful of clinical trials with phage therapy in humans have been reported. BioPhage-PA has been tested
in Phase I/II trials as topical treatment against P. aeruginosa ear
infections and Phase III trials are underway (Wright et al., 2009,
www.biocontrol-ltd.com). Trials are also considered for an aerosol
variant for use in patients with cystic fibrosis (www.biocontrolltd.com). A phage cocktail, BFC-1, containing phages specific for
P. aeruginosa and S. aureus strains is currently being evaluated as
treatment on burn wounds (Merabishvili et al., 2009). Another
phage preparation, WPP-201, also topical, was tested against
venous leg ulcers in a Phase I safety trial (Rhoads et al., 2009,
www.novolytics.co.uk). Nestle, the Swiss food company, conducted
a Phase I safety trial of T4 phage given to healthy volunteers and
recently followed that up by initiating a clinical trial for the use of
phages in an oral rehydration solution given to diarrheal children
(NCT00937274, Bruttin and Brussow, 2005). Recent case reports
describing phage therapy in humans include treatment of bacterial
sepsis, chronic bacterial prostatitis, burn wounds and other ulcers,
as well as eradication of a colonizing MRSA strain (Jikia et al., 2005;
Leszczynski et al., 2006; Letkiewicz et al., 2009; Markoishvili et al.,
2002; Marza et al., 2006; Weber-Dabrowska et al., 2003). Many
of these reports originate from the Institute of Immunology and
Experimental Therapy of the Polish Academy of Sciences. Moreover,
this establishment has an ongoing clinical trial with experimental phage treatment of infections with drug-resistant bacteria
(NCT00945087). On the pre-clinical stage, a number of companies are trying to develop phage-based products for decolonization
of nasal staphylococci (www.gangagen.com, www.intralytix.com,
www.novolytics.co.uk). Phages have been used successfully in
many animal models. This work includes experimental infections
with Burkholderia cenocepacia (Carmody et al., 2010), Enterococcus
faecium (Biswas et al., 2002), Enterococcus faecalis (Uchiyama et al.,
2008), E. coli (Bull et al., 2002; Capparelli et al., 2006; Nishikawa
et al., 2008; Tanji et al., 2005; Wang et al., 2006b), Klebsiella pneumoniae (Chhibber et al., 2008; Vinodkumar et al., 2005; Kumari et al.,
2010), P. aeruginosa (Debarbieux et al., 2010; Heo et al., 2009; Mcvay
et al., 2007; Wang et al., 2006a; Watanabe et al., 2007; Vinodkumar
et al., 2008), Salmonella enterica (Capparelli et al., 2010), S. aureus
(Capparelli et al., 2007; Gupta and Prasad, 2011; Hoshiba et al.,
2010; Matsuzaki et al., 2003; Wills et al., 2005; Zimecki et al., 2009,
2010) and Vibrio vulnificus (Cerveny et al., 2002). An alternative to
the use of whole phage particles is to use lysins. So far, lysins have
only been found that are potent against Gram-positives. Promising in vivo data have been reported on lysins active against Bacillus
anthracis (Schuch et al., 2002; Yoong et al., 2006), Enterococcus spp
(Yoong et al., 2004), S. aureus (Daniel et al., 2010; Rashel et al., 2007),
Streptococcus agalactiae (Cheng and Fischetti, 2007; Cheng et al.,
2005), S. pneumoniae (Entenza et al., 2005; Grandgirard et al., 2008;
Jado et al., 2003; Loeffler et al., 2003, 2001; Mccullers et al., 2007;
Witzenrath et al., 2009) and Streptococcus pyogenes (Nelson et al.,
2001). Bioengineered phages are also a possibility. An example
of this is currently in clinical trials, evaluated for the decolonization of S. aureus (Fairhead, 2009, www.phicotherapeutics.co.uk).
Finally, veterinary applications of phages are under investigation,
especially in poultry (Johnson et al., 2008).
129
Therapeutic antibodies are already on the market, the majority
of them for the treatment of cancer (Reichert et al., 2005). None of
these antibodies have been approved for the treatment of bacterial
infections, but several are undergoing preclinical and clinical trials.
The concept of passive immunization is not a new one: before the
antibiotic era, patients were regularly given antisera prepared from
inoculated horses. Anti-bacterial antibodies can be divided into two
categories: those that bind directly to the pathogen and those that
aim to neutralize toxins or other virulence factors (Bebbington and
Yarranton, 2008). Antibodies that bind directly to the bacteria usually work by opsonizing the bacteria for phagocytosis. Those that
bind to virulence factors disarm the bacteria, thereby giving the
host a chance to clear the infection immunologically.
targeting Pseudomonas quorum sensing (Kaufmann et al., 2006),
alginate (Pier et al., 2004, www.aridispharma.com) and flagellin
(Neville et al., 2005) have been reported. Polyclonal Pseudomonasspecific antibodies produced in hens and transported to the egg
yolk are in clinical use for the treatment of cystic fibrosis patients
in Sweden (Nilsson et al., 2008). These antibodies are not approved
by the European Medicines Agency (EMA) or the FDA, but Phase
III clinical trials are underway (www.immunsystem.se). Antibodies
directed to shiga toxin-producing E. coli are also in development
and two (ShigamAbs and Urtoxazumab) are currently undergoing
clinical trials (Bitzan et al., 2009; Kimura et al., 2002; Lopez et al.,
2010; Mukherjee et al., 2002). Further, the promising results of
a Phase II clinical trial evaluating monoclonal antibodies directed
toward Clostridium difficile were recently published (Babcock et al.,
2006; Lowy et al., 2010). Most of the antibodies described thus far
are directed toward toxins and are very specific to the bacterial
species producing those toxins. A more broad-spectrum antibody
has also been reported targeting the poly-N-acetylglucosamine
(PNAG) of bacterial polysaccharide. This antibody, currently under
preclinical development, has shown in vivo protection toward
both S. aureus and E. coli (Cerca et al., 2007; Pier et al., 2004,
www.alopexx.com).
6. Vaccines
Therapeutic antibodies have the advantage of being very specific, which means that they do not affect the commensal flora.
Intended for systemic use only, they can be produced toward
any pathogen. Indications for antibodies currently in clinical trials
include the prevention of S. aureus infection in high-risk groups,
as well as prophylaxis and treatment of anthrax. Antibodies are
widely used for cancer treatment and thus many questions regarding safety and pharmacokinetics may already have been addressed.
However, as with antivirulence strategies and phage therapy, the
narrow specificity increases the requirements for rapid diagnosis.
Therapeutic antibodies are also relatively costly to produce and are
usually intended for small markets, strongly suggesting that the
final product may be expensive.
6.1. Background
5. Therapeutic antibodies
5.1. Background
Several antibody-based antibacterial drugs are currently being
evaluated in clinical trials (Table 3). However, a number of promising candidates – Veronate, Altastaph and Aurograb – directed toward
S. aureus recently failed Phase II/Phase III studies because of
lack of efficacy (Bebbington and Yarranton, 2008). Many other
staphylococci-specific antibodies have been identified (Brown
et al., 2009; Hall et al., 2003; Ragle and Bubeck Wardenburg, 2009;
Tilahun et al., 2010; Walsh et al., 2004; Park et al., 2007) and
one of these, Pagibaximab, is currently being evaluated for prevention of infection in low-birth-weight infants in clinical trials
(www.biosynexus.com, Weisman et al., 2009). Several studies also
report antibodies that target B. anthracis toxins (Zhou et al., 2008;
Albrecht et al., 2007; Mohamed et al., 2005; Peterson et al., 2006;
Staats et al., 2007; Vitale et al., 2006; Cui et al., 2005; Maynard
et al., 2002; Wild et al., 2003; Chen et al., 2009; Herrmann et al.,
2006; Hull et al., 2005; Zhao et al., 2003). Anthim, Raxibacumab
and Valortim are all anthrax-specific antibodies currently undergoing clinical trials (www.elusys.com, www.pharmathene.com,
Subramanian et al., 2005). Another common target for therapeutic antibodies is P. aeruginosa. KBPA101, a monoclonal directed
toward LPS O polysaccharide of P. aeruginosa serotype O11, is currently undergoing clinical trials (Horn et al., 2010; Lazar et al.,
2009). KB001, also a Pseudomonas-specific antibody inhibiting type
III secretion, is being evaluated in cystic fibrosis patients in clinical
trials (Baer et al., 2009, www.kalobios.com). In addition, antibodies
The oldest vaccines are based on attenuated or killed whole
cells (e.g. BCG against tuberculosis). New techniques have made it
possible to produce vaccines based on modified toxins and proteinconjugated polysaccharides. Suitable antigens have traditionally
been found by the immunization of animals and the identification of immunoreactive proteins. The breakthrough of genomics
has provided novel methods for selecting antigens. Bioinformatics
has made it possible to identify specific groups of proteins, such
as surface-exposed proteins. This way of finding novel antigens
has been called “reverse vaccinology” (Rappuoli, 2000). An alternative method, the ANTIGENome technology, has also been described
(Meinke et al., 2005). Peptide libraries covering the whole genome
of a pathogen are screened for immunogenicity by the addition of
serum from humans previously exposed to the pathogen.
A functional vaccine is probably the most cost-effective antibacterial drug possible. It would be hard to question the usefulness of
the vaccine strategy—after all, it has been used to eradicate smallpox. However, vaccines are used prophylactically, often offered to
general patient populations, i.e. the safety issue is extremely important.
Research into vaccines is so extensive that it is hard to grasp
the full picture. This section will focus on vaccine candidates
currently undergoing clinical trials or in advanced preclinical development. Efforts to develop a P. aeruginosa vaccine have been
ongoing for a long time, but though several have seemed promising in early clinical trials, none have been approved (Doring and
Pier, 2008). However, IC43 has recently completed Phase II clinical trials (NCT00876252). This candidate vaccine is a recombinant
fusion protein of OprF and OprI, two P. aeruginosa outer membrane
proteins (www.intercell.com). Meanwhile, at least three staphylococcal vaccines are currently being evaluated in clinical trials.
V710 is, based on the IsdB protein, involved in iron acquisition
and identified using the ANTIGENome technology (Etz et al., 2002).
130
Table 3
Selected antibacterial therapeutic antibodies in clinical development.
Antibody
Target organism
Company
Reference
Anthim (ETI-204)
Raxibacumab
Valortim (MDX-1303)
CDA1/CDB1
ShigamAbs
Urtoxazumab
Anti-Pseudomonas IgY
KB001
Panobacumab (KBPA101)
Pagibaximab
B. anthracis
B. anthracis
B. anthracis
C. difficile
Shiga toxin-producing E. coli
Shiga toxin-producing E. coli
P. aeruginosa
P. aeruginosa
P. aeruginosa
S. aureus
Elusys Therapeutics
Human Genome Sciences
PharmAthene/Medarex
Medarex/MassBiologics/Merck
Thallion Pharmaceuticals
Teijin
Immunsystem
KaloBios Pharmaceuticals/Sanofi Pasteur
Kenta Biotech
Biosynexus
www.elusys.com
Subramanian et al. (2005)
www.pharmathene.com
Lowy et al. (2010)
Bitzan et al. (2009)
Lopez et al. (2010)
Nilsson et al. (2008)
www.kalobios.com
Lazar et al. (2009)
Weisman et al. (2009)
The other two candidates, GSK2392105A and SA3Ag, are multivalent vaccines containing three and four antigens, respectively
(NCT01160172, NCT01018641). A previous attempt to develop a
staphylococcal vaccine focused on polysaccharides, but this vaccine (StaphVAX) failed to show efficacy in Phase III trials (Schaffer
and Lee, 2008). The polysaccharide strategy has otherwise been
very successful, exemplified by the novel conjugate vaccines that
have been developed toward S. pneumoniae and Neisseria meningitidis. These vaccines show good efficacy but do not cover all
clinically important strains. Therefore, efforts are made to develop
vaccines with better coverage. At least one pneumococcal nonpolysaccharide vaccine, IC47, is currently being evaluated in clinical
trials. It is a multivalent vaccine containing three broadly conserved
protein antigens (Giefing et al., 2008, www.intercell.com). Another
interesting candidate, killed whole cell vaccine (WCV), has shown
potency in animal models and clinical trials are in preparation
(Malley, 2010; Lu et al., 2010). For meningococci, serogroup B has
been especially difficult to target because its polysaccharide is identical to a human one. A couple of vaccines based on outer membrane
vesicles (OMVs) have been used locally, but no universal one has
been approved. Several are now in clinical trials (Granoff, 2010),
including variants based on multiple bioengineered strains (Van
Den Dobbelsteen et al., 2007; Zollinger et al., 2010). Two promising
protein-based vaccines are also undergoing clinical trials (Gorringe
and Van Alphen, 2009), one containing two variants of a lipoprotein
(rLP2086) (Fletcher et al., 2004) and one containing five antigens
engineered into three recombinant proteins (Giuliani et al., 2006;
Pizza et al., 2000). Efficient vaccines are also lacking against Group
A streptococci (GAS) and Group B streptococci (GBS). StreptAvax, a
26-valent GAS vaccine candidate based on the M protein antigen,
was recently evaluated in a Phase I clinical trial (Kotloff et al., 2004).
Other GAS vaccines are in preclinical development, including PepVac StreptInCor, which is based on the conserved parts of the M
protein (Brandt et al., 2000; Guilherme et al., 2009), as well as two
protein-based candidates with novel antigens identified via reverse
vaccinology (Rodriguez-Ortega et al., 2006) and the ANTIGENome
technology (Fritzer et al., 2010). For GBS, the most common strategy
has been to use polysaccharide conjugates and several monovalent
or divalent candidates have been tested in clinical trials (Edwards,
2008). One 4-valent candidate is currently undergoing clinical trials (NCT01150123). Protein-based candidates, however, are under
development (Maione et al., 2005; Doro et al., 2009). When it comes
to vaccines toward gastrointestinal pathogens, several candidates
are under evaluation for prevention of enterotoxigenic E. coli (ETEC)
disease (NCT01060748, NCT00993681). One C. difficile candidate,
based on toxoids, is being evaluated in clinical trials (Kotloff et al.,
2001). Other E. coli variants in addition to ETEC have been targeted
in vaccine research. Several promising candidates have failed in late
stage clinical trials, and are no longer in clinical evaluation. Two
recent publications, however, identify novel antigens for future
vaccine development (Alteri et al., 2009; Moriel et al., 2010). Finally,
even though there is a licensed vaccine for protection against tuberculosis, efforts are being made to develop one with better efficacy.
Several candidates are being evaluated in clinical trials. Hybride-1
is based on a fusion protein of Ag85B and ESAT-6 (Weinrich Olsen
et al., 2001) and Mtb72F/AS02A contains two antigens selected for
their ability to boost pre-existing immunity induced by BCG or TB
infection (Von Eschen et al., 2009). AERAS-402/Crucell Ad35 (Abel
et al., 2010) and MVA85A/AERAS 485 (Mcshane et al., 2004) are two
additional candidates, both based on virus vectors.
7. Potentiators of currently used antibiotics
7.1. Background
An alternative to the development of novel antibiotics is to find
potentiators of the already existing ones. These potentiators could
function either by reversing resistance mechanisms in naturally
sensitive pathogens or by sensitizing naturally resistant strains. The
most common resistance mechanism toward clinically important
beta-lactams is the production of beta-lactamases or alternative
penicillin-binding proteins (PBPs). Treatment with a beta-lactam in
combination with a beta-lactamase inhibitor is already used clinically, and three inhibitors have been registered: clavulanic acid,
tazobactam and sulbactam (Drawz and Bonomo, 2010). Another
resistance mechanism common among Gram-negatives is the overexpression of efflux pumps. This is also a possible target for
potentiators, although no therapeutic efflux pump inhibitors are
currently available on the market.
The good news about potentiators is that they work, i.e. we
already have them in the clinic. The bad news is that resistance to
beta-lactamase inhibitors has been reported (Buynak, 2006). Most
beta-lactamase inhibitors under preclinical investigation have been
developed for use against Gram-negatives such as P. aeruginosa and
E. coli. These bacteria, and S. aureus, are typical targets also for the
novel efflux pump inhibitors.
Several novel beta-lactamase inhibitors are currently being
investigated. NXL104 is active against class A and C beta-lactamases,
with shown potency in several Gram-negatives, including E. coli and
K. pneumoniae (Stachyra et al., 2009). It is being evaluated in Phase
II clinical trials in combination with ceftazidime. ME1071 (CP3242),
currently undergoing clinical trials in Japan (www.meiji.com,
Ishii et al., 2010), has shown efficacy in Gram-negatives such as
P. aeruginosa, A. baumannii, E. coli and K. pneumoniae. BLI-489
is a penem-based inhibitor with potency in combination with
piperacillin in experimental infections with piperacillin-resistant
E. coli and E. cloacae (Petersen et al., 2009). Several other agents
with beta-lactamase inhibitory properties have been reported,
including the 6-alkylidenepenem sulfones (Pattanaik et al., 2009),
the oxapenem analogues (Simpson et al., 2003), LK-157 (Paukner
et al., 2009) and BAL30376 (a combination of three inhibitors)
(www.basilea.com). The other major area of research within this
field is the development of efflux pump inhibitors. Examples of
compounds reported for Gram-negatives include pyridopyrimidine
derivatives active in P. aeruginosa (Yoshida et al., 2007; Lomovskaya
et al., 2001), aryl-piperazines for use in E. coli, Acinetobacter, Klebsiella and Enterobacter (Schumacher et al., 2006; Pannek et al., 2006;
Kern et al., 2006), quinolines for Enterobacter (Chevalier et al., 2001)
and more recently quinazolines active in Enterobacter, Klebsiella
and P. aeruginosa (Chevalier et al., 2010). Inhibitors with activity
in Gram-positives have also been identified, especially for S. aureus
(Sangwan et al., 2008; Vidaillac et al., 2007; German et al., 2008).
As yet, no efflux pump inhibitor has been approved for clinical use.
One candidate, MP-601,205, with intended use in combination with
fluoroquinolone antibiotics, was tested in clinical trials but these
trials were not pursued because of tolerability issues (Lomovskaya
et al., 2007). Efflux pump inhibitors, however, are still included in
the developmental programs of Mpex, the company that identified
MP-601,205 (www.mpexpharma.com). Other creative examples of
potentiating currently used antibiotics include the use of bioengineered phages (Lu and Collins, 2009) as well as activating a drug
toward a pathogen that is naturally resistant to it, as exemplified by
the combined use of meropenem and clavulanate to treat successfully tuberculosis in mice (Hugonnet et al., 2009). Another approach
was reported last year when it was shown that targeting a regulator of stress response (AmgRS) in P. aeruginosa led to increased
tobramycin sensitivity (Lee et al., 2009). A similar strategy, targeting the bacterial SOS response, is under preclinical development
(www.achaogen.com).
8. Antibacterial biomaterials
8.1. Background
Bacterial infections at the sites of implanted medical devices
are conditions of immense clinical importance. Both permanent
implants and short-term biomedical devices such as catheters
and endotracheal tubes may be colonized. Urinary tract infections
related to catheters are the most prevalent form of nosocomial
infections (Klevens et al., 2007). Bacterial biofilm formation on the
medical device is the main reason for the high prevalence of infections. For devices used in urology, especially urinary catheters and
ureteral stents, growth of bacteria may not only lead to infection but
also to a phenomenon known as encrustation. Basically, urease produced by the infecting agent hydrolyzes urea present in the urine,
resulting in an elevation of pH, ultimately leading to precipitation of
salts and deposition of crystals on the surface (Morris and Stickler,
1998). Encrustation may lead to blockage of the catheter and severe
complications. The bacteria most commonly associated with infections on medical devices are staphylococcal species, except for
the ones on urinary devices, where Gram-negatives (e.g., E. coli, P.
aeruginosa, Enterobacter aerogenes, Acinetobacter acinus, Klebsiella
spp and Proteus spp) are most common (Leone et al., 2003). Proteus
mirabilis is the pathogen most commonly associated with encrustation (Morris and Stickler, 1998). Attempts made to reduce the
medical implant-related infections include systemic antibiotic prophylaxis as well as local administration of antimicrobial agents.
The severity of device-related infections ranges between relatively
mild infections to life-threatening conditions, with consequences
of health risks for the patients as well as higher costs because of
replacements of infected implants and prolonged hospitalizations.
Efforts to develop medical devices with antibacterial properties have been ongoing for a long time. Most polymeric materials
131
commonly used for medical devices such as catheters are easily colonized by bacteria. Therefore, efforts have been exerted to
add antibacterial surface coatings onto the devices. These coatings
may release antibacterial compounds, have antibacterials covalently bound to them or in themselves be resistant to bacterial
colonization. Central venous catheters (CVCs) and urinary catheters
with antibacterial coating are on the market (Hockenhull et al.,
2009). The same strategy is under investigation for implants for
orthopedic joint replacements most commonly made of titanium,
stainless steel or other metal alloys. These materials show excellent biocompatibility as well as high-quality mechanical properties,
but are not resistant to bacterial colonization. The most common
antibacterial coatings in use today are those containing silver. Silver is known for its potent broad-spectrum antibacterial activity
toward both Gram-positives and Gram-negatives, which is believed
to be attributed to the release of silver ions (Monteiro et al.,
2009). Coatings releasing antibiotics are also available. Concerns
regarding these kinds of devices include silver toxicity as well
as resistance development (Monteiro et al., 2009; Hamill et al.,
2007).
Within the field of urology, research on antibacterial devices
mainly focuses on urinary catheters and ureteral stents. Several
catheters with antibacterial coating are available, including variants with silver alloys and antibiotics (Schumm and Lam, 2008).
Numerous clinical trials have been undertaken to evaluate the
efficacy of these coatings. Recently, a meta-analysis of all these trials was performed (Schumm and Lam, 2008) showing that silver
alloy catheters reduced the incidence of asymptomatic bacteriuria during short-term urinary catheterization. Catheters coated
with minocycline/rifampicin or nitrofurazone reduced the incidence after a week, but when measured later the reduction was
not significant (Schumm and Lam, 2008). The clinical implications
of these results have been questioned, however (Stickler, 2008).
Novel, investigational antibacterial coatings are under development. The antiseptic triclosan has shown good efficacy in several
in vitro and in vivo studies (Chew et al., 2006; Cadieux et al.,
2006). A triclosan-eluting stent is currently being evaluated in
a Phase II clinical trial (Cadieux et al., 2009). Gendine-coated
catheters have also been investigated in animal studies with
promising results (Hachem et al., 2009). Several other antibacterials have shown efficacy in animal models with catheters,
including chloroxylenol/thymol (Mansouri and Darouiche, 2008)
and chlorhexidine/protamine sulphate (Darouiche et al., 2008). An
innovative strategy that has been tested in clinical trials is “bacterial interference” (Trautner et al., 2007; Prasad et al., 2009). The
catheters are precolonized with an avirulent E. coli strain before
insertion, potentially preventing adherence of virulent strains.
Just as for urinary catheters, CVCs with antibacterial properties
are commercially available, including variants impregnated with
silver, silver/platinum/carbon, chlorhexidine/silver sulphadiazine,
minocycline/rifampicin and heparin (Hockenhull et al., 2009). Their
usefulness has been debated, but recent meta-analyses concluded
that antibacterial coatings do have a beneficial effect on the rate
of device-derived infections, especially minocycline/rifampicin
(Hockenhull et al., 2009; Wang et al., 2010). Other alternative coatings for CVCs that have been investigated include N-acetylcysteine
(Mansouri and Darouiche, 2007), triclosan/DispersinB (Darouiche
et al., 2009) and gendine (Hanna et al., 2006). A novel, 5fluorouracil-coated variant has recently completed Phase III clinical
trials with encouraging results (Walz et al., 2010). For permanent implants based on metal alloys, coating strategies are also
under investigation. Antibiotics such as gentamicin have traditionally been used in bone cement for prophylactic local delivery.
132
Presently, cementless bone implants are more routinely used,
increasing the need for other antibacterial strategies. The task
is somewhat more challenging than for non-permanent devices
because osseointegration has to be taken into account. Calcium
phosphate-based coatings have shown good biocompatibility and
may be used as carriers for antibacterials (Radin et al., 1997).
Promising in vivo data have been reported for calcium hydroxyapatite in combination with tobramycin (Moojen et al., 2009) and
gentamicin (Alt et al., 2006). Other strategies include polymerization of vancomycin onto the implant (Lawson et al., 2007), direct
spraying of the implant with antibiotics in methanol (Aykut et al.,
2010; Darouiche et al., 2007), as well as using poly(D,L-lactide)
(PDLLA) (Kalicke et al., 2006; Vester et al., 2010) or sol-gel as
carriers. A recent publication describes the successful use of silvercoated megaprostheses in a clinical trial of patients with bone
sarcoma (Hardes et al., 2010). Silver coating resulted in a reduction
in infections as well as fewer amputations (Hardes et al., 2010).
Finally, the concepts of the other fields of this report have also
been applied to prevent bacterial colonization of medical devices.
This includes directly targeting biofilm formation on biomaterials
using quorum-sensing inhibitors (Cirioni et al., 2007; Lovetri and
Madhyastha, 2010, Anguita-Alonso et al., 2007, Cirioni et al., 2006;
Christensen et al., 2007), as well as attempting to eradicate the bacteria using bacteriophages (Fu et al., 2010; Curtin and Donlan, 2006;
Carson et al., 2010) or AMPs (Trautner et al., 2005; Minardi et al.,
2007).
9. Discussion
Several publications have reported that the big pharmaceutical companies are cutting down on research aimed at finding
new therapeutics for the treatment of bacterial infections, citing
a less favorable economic incentive compared with medications
for chronic medical conditions (Boucher et al., 2009). Novel strategies, however, are under investigation, both within the academic
community and in biotech/pharmaceutical companies. Many of the
fields examined in this report have not yet generated products
approved by the EMA or the FDA, but candidates are in clinical trials. Most of these candidates have narrow specificity spectra and
would probably not have been considered during the “golden age”
of antibiotics. Yet, in times of emerging resistance, all additional
antibacterial drugs are welcome. The more diverse our arsenal
against bacterial pathogens becomes, the better will be the range of
tailored treatment alternatives that can be offered. Broad-spectrum
antibiotics are not always the best choice, especially not when
considering the commensal flora and the risk for opportunistic
infections. However, to take advantage fully of the alternative
antibiotics under development, new diagnostics are needed that
are more precise and faster than those in use today. The importance of better diagnostics for these novel antibacterial approaches
to become successful cannot be stressed enough in today’s complex
medical environment.
Anti-virulence approaches, phage therapy and therapeutic antibodies are fields that will yield drugs with high specificity and
hence narrow spectra. They are all still awaiting their first drug
approved for market authorization. To this date, only one antivirulence non-antibody candidate, Synsorb-Pk, has entered clinical
trials (Trachtman et al., 2003). In theory, antivirulence strategies
are tempting both because of the specificity of the resulting drugs
and because of the low selective pressure for resistance development. These drugs, however, are at least a decade away and it is
questionable whether they will ever be used as first-line drugs
for life-threatening conditions (e.g. sepsis) when time is limited.
Because of their narrow specificity, the same holds for therapeutic
antibodies though these are a bit further in development. Although
the regulatory authorities have turned down several candidates, it
is still a promising field. Antibody-based drugs are common within
oncology and inflammatory disease and recently the first virusspecific antibody, palivizumb, for treatment of RSV infection, was
approved. With several antibacterial antibodies in late-stage clinical development, it is probably just a question of time before the
first one will be in the clinics.
It has to be acknowledged that phage therapy is already in clinical use, even though parts of the Western world are not aware of it.
Although the available literature within this field is largely limited
to case studies and uncontrolled trials, phage therapy appears to
be an alternative for certain indications. For complicated wounds
and ulcers caused by multidrug-resistant bacteria, phage therapy
could be an option. In the EU, it has been proposed that specific sections concerning phage therapy should be included in the Advanced
Therapy Medicinal Product Regulation to make it easier to get
approval for clinical trials involving such therapy (Verbeken et al.,
2007). It may be easier, though, to get approval for lysins than for
full phage particles. Interestingly, thus far, resistance development
toward lysins has not been observed. However, most lysins are only
stable in vivo for less than 30 min (Loeffler et al., 2003), making
stability one of the issues that has to be solved before clinical use.
Just as for therapeutic antibodies, the field of AMPs has had several candidates in late-stage clinical trials that failed to be approved
for clinical use. Some of these disapprovals have been questioned
and it is possible that candidates such as pexiganan would have
been approved if trials had been designed differently (Moore, 2003).
Most AMPs have quite broad spectra, but because of stability and
toxicity problems, they are mainly evaluated for topical use. Just
as bacteriophages, they have the potential to fill the niche as topical therapeutics toward complicated wounds and ulcers. Another
possible application for AMPs is as decolonizers. It will be interesting to follow the development of plectasin and the improved
version of it in that these candidates seem to have the potential
to be used systemically. Further, AMPs with immunomodulatory
properties have gained recent interest and may find future use as
anti-inflammatory agents.
Improvement of existing drugs has become the most successful way of generating novel antibiotics. It works well and several
candidates of traditional classes are in late-stage clinical development, such as the cephalosporin ceftaroline (Corey et al., 2010), the
tetracycline amadacycline (PTK0796), the streptogramin NXL-103
(Politano and Sawyer, 2010) and the macrolide CEM-101 (Woosley
et al., 2010). However, all these candidates have a limited lifespan
in that eventually resistance will develop. This situation may be
what we have to get used to, i.e. the continued development of new
drugs that can replace those already in clinical practice. An alternative would be successful vaccination strategies. It will be of special
interest to follow the new vaccine candidates that have been identified through genomics and proteomics. These candidates represent
genuinely novel approaches and the first one to be approved may
well be the beginning of a new era. Moreover, the development of
medical devices more resistant to bacterial adherence may reduce
the rate of infections and hence limit the need for antibiotics. Even
though many of the coatings that are evaluated and in use today
involve traditional antibiotics, several take advantage of different
alternatives such as silver and antiseptics.
Again, most of these alternative drugs could only replace
the currently used antibiotics if efficient diagnostics are developed in parallel. This strategy is also attempted by the company
developing the Pseudomonas monoclonal antibody KBPA101
(www.kentabiotech.com). Still, even if these novel drugs cannot
replace antibiotics, they may become a much-needed complement
to the drugs in use today. The overuse of antibiotics has left us in
our current predicament. We need to learn from that mistake and
take better care of the drugs that are still viable.
10. Methods
The PubMed database was searched using the search terms
“antimicrobial peptides”, “antivirulence”, “phage therapy”, therapeutic antibodies”, “efflux pump inhibitor”, “beta-lactamase
inhibitor”,“biomaterial”, “implant” and “vaccine” in combination with the terms “novel” or “antibacterial”, or both. For
the vaccine field, “vaccine” was also combined with the
names of bacterial species considered especially important.
Further searches on PubMed were performed based on the
authors/companies/substances that were received in the first
round. Only publications written in English and published in the
past ten years were included, unless an earlier publication was
regarded as particularly interesting. Company web pages and
ClinicalTrials.gov were subsequently searched for updates on the
developmental stages.
Acknowledgements
I would like to express my sincere gratitude to the panel of
advisers, Charlotta Edlund, Vincent Fischetti, Bengt Gårdlund, Victor Nizet and John Turnidge, who critically read parts or all of the
manuscript. Their comments have greatly improved the quality of
the report. This work is based on the previous report “An Overview
of Ongoing Research Aimed at Finding Novel Antibacterial Drugs”,
which was produced in preparation for the EU meeting “Conference Innovative Incentives for Effective Antibacterials” (held in
Stockholm, September 17, 2009) on assignment of the Swedish
Government. We gratefully acknowledge the financial support of
VINNOVA and ReAct.
References
Abel, B., Tameris, M., Mansoor, N., Gelderbloem, S., Hughes, J., Abrahams, D.,
Makhethe, L., Erasmus, M., De Kock, M., Van Der Merwe, L., Hawkridge, A.,
Veldsman, A., Hatherill, M., Schirru, G., Pau, M.G., Hendriks, J., Weverling, G.J.,
Goudsmit, J., Sizemore, D., Mcclain, J.B., Goetz, M., Gearhart, J., Mahomed, H.,
Hussey, G.D., Sadoff, J.C., Hanekom, W.A., 2010. The novel tuberculosis vaccine,
AERAS-402, induces robust and polyfunctional CD4+ and CD8+ T cells in adults.
Am. J. Respir. Crit. Care. Med. 181, 1407–1417.
Aiello, D., Williams, J.D., Majgier-Baranowska, H., Patel, I., Peet, N.P., Huang, J., Lory,
S., Bowlin, T.L., Moir, D.T., 2010. Discovery and characterization of inhibitors of
Pseudomonas aeruginosa type III secretion. Antimicrob. Agents Chemother. 54,
1988–1999.
Albrecht, M.T., Li, H., Williamson, E.D., Lebutt, C.S., Flick-Smith, H.C., Quinn, C.P.,
Westra, H., Galloway, D., Mateczun, A., Goldman, S., Groen, H., Baillie, L.W.,
2007. Human monoclonal antibodies against anthrax lethal factor and protective antigen act independently to protect against Bacillus anthracis infection and
enhance endogenous immunity to anthrax. Infect. Immun. 75, 5425–5433.
Alt, V., Bitschnau, A., Osterling, J., Sewing, A., Meyer, C., Kraus, R., Meissner,
S.A., Wenisch, S., Domann, E., Schnettler, R., 2006. The effects of combined
gentamicin-hydroxyapatite coating for cementless joint prostheses on the
reduction of infection rates in a rabbit infection prophylaxis model. Biomaterials
27, 4627–4634.
Alteri, C.J., Hagan, E.C., Sivick, K.E., Smith, S.N., Mobley, H.L., 2009. Mucosal immunization with iron receptor antigens protects against urinary tract infection.
PLoS Pathog. 5, e1000586.
Andes, D., Craig, W., Nielsen, L.A., Kristensen, H.H., 2009. In vivo pharmacodynamic
characterization of a novel plectasin antibiotic, NZ2114, in a murine infection
model. Antimicrob. Agents Chemother. 53, 3003–3009.
Anguita-Alonso, P., Giacometti, A., Cirioni, O., Ghiselli, R., Orlando, F., Saba, V., Scalise,
G., Sevo, M., Tuzova, M., Patel, R., Balaban, N., 2007. RNAIII-inhibiting-peptideloaded polymethylmethacrylate prevents in vivo Staphylococcus aureus biofilm
formation. Antimicrob. Agents Chemother. 51, 2594–2596.
Armstrong, G.D., Fodor, E., Vanmaele, R., 1991. Investigation of Shiga-like toxin
binding to chemically synthesized oligosaccharide sequences. J. Infect. Dis. 164,
1160–1167.
Arnoldo, A., Curak, J., Kittanakom, S., Chevelev, I., Lee, V.T., Sahebol-Amri, M.,
Koscik, B., Ljuma, L., Roy, P.J., Bedalov, A., Giaever, G., Nislow, C., Merrill, A.R.,
Lory, S., Stagljar, I., 2008. Identification of small molecule inhibitors of Pseudomonas aeruginosa exoenzyme S using a yeast phenotypic screen. PLoS Genet.
4, e1000005.
Aykut, S., Ozturk, A., Ozkan, Y., Yanik, K., Ilman, A.A., Ozdemir, R.M., 2010. Evaluation
and comparison of the antimicrobial efficacy of teicoplanin- and clindamycincoated titanium implants: an experimental study. J. Bone Joint Surg. Br. 92,
159–163.
133
Babcock, G.J., Broering, T.J., Hernandez, H.J., Mandell, R.B., Donahue, K., Boatright,
N., Stack, A.M., Lowy, I., Graziano, R., Molrine, D., Ambrosino, D.M., Thomas
Jr., W.D., 2006. Human monoclonal antibodies directed against toxins A and B
prevent Clostridium difficile-induced mortality in hamsters. Infect. Immun. 74,
6339–6347.
Baer, M., Sawa, T., Flynn, P., Luehrsen, K., Martinez, D., Wiener-Kronish, J.P., Yarranton, G., Bebbington, C., 2009. An engineered human antibody fab fragment
specific for Pseudomonas aeruginosa PcrV antigen has potent antibacterial activity. Infect. Immun. 77, 1083–1090.
Balaban, N., Goldkorn, T., Nhan, R.T., Dang, L.B., Scott, S., Ridgley, R.M., Rasooly, A.,
Wright, S.C., Larrick, J.W., Rasooly, R., Carlson, J.R., 1998. Autoinducer of virulence
as a target for vaccine and therapy against Staphylococcus aureus. Science 280,
438–440.
Banin, E., Lozinski, A., Brady, K.M., Berenshtein, E., Butterfield, P.W., Moshe, M.,
Chevion, M., Greenberg, E.P., Banin, E., 2008. The potential of desferrioxaminegallium as an anti-Pseudomonas therapeutic agent. Proc. Natl. Acad. Sci. U. S. A.
105, 16761–16766.
Bebbington, C., Yarranton, G., 2008. Antibodies for the treatment of bacterial infections: current experience and future prospects. Curr. Opin. Biotechnol. 19,
613–619.
Berkowitz, B.A., Bevins, C.L., Zasloff, M.A., 1990. Magainins: a new family of
membrane-active host defense peptides. Biochem. Pharmacol. 39, 625–629.
Biswas, B., Adhya, S., Washart, P., Paul, B., Trostel, A.N., Powell, B., Carlton, R., Merril,
C.R., 2002. Bacteriophage therapy rescues mice bacteremic from a clinical isolate
of vancomycin-resistant Enterococcus faecium. Infect. Immun. 70, 204–210.
Bitzan, M., Poole, R., Mehran, M., Sicard, E., Brockus, C., Thuning-Roberson, C., Riviere,
M., 2009. Safety and pharmacokinetics of chimeric anti-Shiga toxin 1 and antiShiga toxin 2 monoclonal antibodies in healthy volunteers. Antimicrob. Agents
Chemother. 53, 3081–3087.
Boldt, G.E., Kennedy, J.P., Janda, K.D., 2006. Identification of a potent botulinum neurotoxin a protease inhibitor using in situ lead identification chemistry. Org. Lett.
8, 1729–1732.
Boucher, H.W., Talbot, G.H., Bradley, J.S., Edwards, J.E., Gilbert, D., Rice, L.B., Scheld,
M., Spellberg, B., Bartlett, J., 2009. Bad bugs, no drugs: no ESKAPE! An update
from the Infectious Diseases Society of America. Clin. Infect. Dis. 48, 1–12.
Bowdish, D.M., Davidson, D.J., Hancock, R.E., 2005. A re-evaluation of the role of host
defence peptides in mammalian immunity. Curr. Protein Pept. Sci. 6, 35–51.
Brandt, E.R., Sriprakash, K.S., Hobb, R.I., Hayman, W.A., Zeng, W., Batzloff, M.R.,
Jackson, D.C., Good, M.F., 2000. New multi-determinant strategy for a group
A streptococcal vaccine designed for the Australian Aboriginal population. Nat.
Med. 6, 455–459.
Brinch, K.S., Tulkens, P.M., Van Bambeke, F., Frimodt-Moller, N., Hoiby, N., Kristensen,
H.H., 2010. Intracellular activity of the peptide antibiotic NZ2114: studies with
Staphylococcus aureus and human THP-1 monocytes, and comparison with daptomycin and vancomycin. J. Antimicrob. Chemother. 65, 1720–1724.
Brown, M., Kowalski, R., Zorman, J., Wang, X.M., Towne, V., Zhao, Q., Secore, S.,
Finnefrock, A.C., Ebert, T., Pancari, G., Isett, K., Zhang, Y., Anderson, A.S., Montgomery, D., Cope, L., Mcneely, T., 2009. Selection and characterization of murine
monoclonal antibodies to Staphylococcus aureus iron-regulated surface determinant B with functional activity in vitro and in vivo. Clin. Vaccine Immunol. 16,
1095–1104.
Bruttin, A., Brussow, H., 2005. Human volunteers receiving Escherichia coli phage
T4 orally: a safety test of phage therapy. Antimicrob. Agents Chemother. 49,
2874–2878.
Bull, J.J., Levin, B.R., Derouin, T., Walker, N., Bloch, C.A., 2002. Dynamics of success
and failure in phage and antibiotic therapy in experimental infections. BMC
Microbiol. 2, 35.
Burnett, J.C., Schmidt, J.J., Stafford, R.G., Panchal, R.G., Nguyen, T.L., Hermone, A.R.,
Vennerstrom, J.L., Mcgrath, C.F., Lane, D.J., Sausville, E.A., Zaharevitz, D.W., Gussio, R., Bavari, S., 2003. Novel small molecule inhibitors of botulinum neurotoxin
A metalloprotease activity. Biochem. Biophys. Res. Commun. 310, 84–93.
Buynak, J.D., 2006. Understanding the longevity of the beta-lactam antibiotics and
of antibiotic/beta-lactamase inhibitor combinations. Biochem. Pharmacol. 71,
930–940.
Cadieux, P.A., Chew, B.H., Knudsen, B.E., Dejong, K., Rowe, E., Reid, G., Denstedt, J.D.,
2006. Triclosan loaded ureteral stents decrease proteus mirabilis 296 infection
in a rabbit urinary tract infection model. J. Urol. 175, 2331–2335.
Cadieux, P.A., Chew, B.H., Nott, L., Seney, S., Elwood, C.N., Wignall, G.R., Goneau,
L.W., Denstedt, J.D., 2009. Use of triclosan-eluting ureteral stents in patients
with long-term stents. J. Endourol. 23, 1187–1194.
Capparelli, R., Nocerino, N., Iannaccone, M., Ercolini, D., Parlato, M., Chiara, M., Iannelli, D., 2010. Bacteriophage therapy of Salmonella enterica: a fresh appraisal
of bacteriophage therapy. J. Infect. Dis. 201, 52–61.
Capparelli, R., Parlato, M., Borriello, G., Salvatore, P., Iannelli, D., 2007. Experimental phage therapy against Staphylococcus aureus in mice. Antimicrob. Agents
Chemother. 51, 2765–2773.
Capparelli, R., Ventimiglia, I., Roperto, S., Fenizia, D., Iannelli, D., 2006. Selection
of an Escherichia coli O157:H7 bacteriophage for persistence in the circulatory system of mice infected experimentally. Clin. Microbiol. Infect. 12,
248–253.
Carmody, L.A., Gill, J.J., Summer, E.J., Sajjan, U.S., Gonzalez, C.F., Young, R.F., Lipuma,
J.J., 2010. Efficacy of bacteriophage therapy in a model of Burkholderia cenocepacia pulmonary infection. J. Infect. Dis. 201, 264–271.
Carson, L., Gorman, S.P., Gilmore, B.F., 2010. The use of lytic bacteriophages in the
prevention and eradication of biofilms of Proteus mirabilis and Escherichia coli.
FEMS Immunol. Med. Microbiol. 59, 447–455.
134
Cegelski, L., Pinkner, J.S., Hammer, N.D., Cusumano, C.K., Hung, C.S., Chorell, E., Aberg,
V., Walker, J.N., Seed, P.C., Almqvist, F., Chapman, M.R., Hultgren, S.J., 2009.
Small-molecule inhibitors target Escherichia coli amyloid biogenesis and biofilm
formation. Nat. Chem. Biol. 5, 913–919.
Cerca, N., Maira-Litran, T., Jefferson, K.K., Grout, M., Goldmann, D.A., Pier, G.B., 2007.
Protection against Escherichia coli infection by antibody to the Staphylococcus
aureus poly-N-acetylglucosamine surface polysaccharide. Proc. Natl. Acad. Sci.
U. S. A. 104, 7528–7533.
Cerveny, K.E., Depaola, A., Duckworth, D.H., Gulig, P.A., 2002. Phage therapy of local
and systemic disease caused by Vibrio vulnificus in iron-dextran-treated mice.
Infect. Immun. 70, 6251–6262.
Chen, Z., Moayeri, M., Zhao, H., Crown, D., Leppla, S.H., Purcell, R.H., 2009. Potent
neutralization of anthrax edema toxin by a humanized monoclonal antibody
that competes with calmodulin for edema factor binding. Proc. Natl. Acad. Sci.
U. S. A. 106, 13487–13492.
Cheng, Q., Fischetti, V.A., 2007. Mutagenesis of a bacteriophage lytic enzyme PlyGBS
significantly increases its antibacterial activity against group B streptococci.
Appl. Microbiol. Biotechnol. 74, 1284–1291.
Cheng, Q., Nelson, D., Zhu, S., Fischetti, V.A., 2005. Removal of group B streptococci colonizing the vagina and oropharynx of mice with a bacteriophage lytic
enzyme. Antimicrob. Agents Chemother. 49, 111–117.
Chenna, B.C., King, J.R., Shinkre, B.A., Glover, A.L., Lucius, A.L., Velu, S.E., 2010. Synthesis and structure activity relationship studies of novel Staphylococcus aureus
Sortase A inhibitors. Eur. J. Med. Chem. 45, 3752–3761.
Chew, B.H., Cadieux, P.A., Reid, G., Denstedt, J.D., 2006. In-vitro activity of triclosaneluting ureteral stents against common bacterial uropathogens. J. Endourol. 20,
949–958.
Chevalier, J., Atifi, S., Eyraud, A., Mahamoud, A., Barbe, J., Pages, J.M., 2001. New
pyridoquinoline derivatives as potential inhibitors of the fluoroquinolone efflux
pump in resistant Enterobacter aerogenes strains. J. Med. Chem. 44, 4023–4026.
Chevalier, J., Mahamoud, A., Baitiche, M., Adam, E., Viveiros, M., Smarandache, A.,
Militaru, A., Pascu, M.L., Amaral, L., Pages, J.M., 2010. Quinazoline derivatives
are efficient chemosensitizers of antibiotic activity in Enterobacter aerogenes,
Klebsiella pneumoniae and Pseudomonas aeruginosa resistant strains. Int. J.
Antimicrob. Agents 36, 164–168.
Chhibber, S., Kaur, S., Kumari, S., 2008. Therapeutic potential of bacteriophage in
treating Klebsiella pneumoniae B5055-mediated lobar pneumonia in mice. J.
Med. Microbiol. 57, 1508–1513.
Choi, S., Isaacs, A., Clements, D., Liu, D., Kim, H., Scott, R.W., Winkler, J.D., Degrado,
W.F., 2009. De novo design and in vivo activity of conformationally restrained
antimicrobial arylamide foldamers. Proc. Natl. Acad. Sci. U. S. A. 106, 6968–6973.
Christensen, L.D., Moser, C., Jensen, P.O., Rasmussen, T.B., Christophersen, L., Kjelleberg, S., Kumar, N., Hoiby, N., Givskov, M., Bjarnsholt, T., 2007. Impact of
Pseudomonas aeruginosa quorum sensing on biofilm persistence in an in vivo
intraperitoneal foreign-body infection model. Microbiology 153, 2312–2320.
Cirioni, O., Ghiselli, R., Minardi, D., Orlando, F., Mocchegiani, F., Silvestri, C., Muzzonigro, G., Saba, V., Scalise, G., Balaban, N., Giacometti, A., 2007. RNAIII-inhibiting
peptide affects biofilm formation in a rat model of staphylococcal ureteral stent
infection. Antimicrob. Agents Chemother. 51, 4518–4520.
Cirioni, O., Giacometti, A., Ghiselli, R., Dell’acqua, G., Orlando, F., Mocchegiani, F.,
Silvestri, C., Licci, A., Saba, V., Scalise, G., Balaban, N., 2006. RNAIII-inhibiting
peptide significantly reduces bacterial load and enhances the effect of antibiotics
in the treatment of central venous catheter-associated Staphylococcus aureus
infections. J. Infect. Dis. 193, 180–186.
Corey, G.R., Wilcox, M., Talbot, G.H., Friedland, H.D., Baculik, T., Witherell, G.W.,
Critchley, I., Das, A.F., Thye, D., 2010. Integrated Analysis of CANVAS 1 and 2:
Phase 3, Multicenter, Randomized, Double-Blind Studies to Evaluate the Safety
and Efficacy of Ceftaroline versus Vancomycin plus Aztreonam in Complicated
Skin and Skin-Structure Infection. Clin. Infect. Dis. 51, 641–650.
Cui, X., Li, Y., Moayeri, M., Choi, G.H., Subramanian, G.M., Li, X., Haley, M., Fitz, Y.,
Feng, J., Banks, S.M., Leppla, S.H., Eichacker, P.Q., 2005. Late treatment with a protective antigen-directed monoclonal antibody improves hemodynamic function
and survival in a lethal toxin-infused rat model of anthrax sepsis. J. Infect. Dis.
191, 422–434.
Curtin, J.J., Donlan, R.M., 2006. Using bacteriophages to reduce formation of
catheter-associated biofilms by Staphylococcus epidermidis. Antimicrob. Agents
Chemother. 50, 1268–1275.
Daniel, A., Euler, C., Collin, M., Chahales, P., Gorelick, K.J., Fischetti, V.A., 2010. Synergism between a novel chimeric lysin and oxacillin protects against infection
by methicillin-resistant Staphylococcus aureus. Antimicrob. Agents Chemother.
54, 1603–1612.
Darouiche, R.O., Mansouri, M.D., Gawande, P.V., Madhyastha, S., 2008. Efficacy of
combination of chlorhexidine and protamine sulphate against device-associated
pathogens. J. Antimicrob. Chemother. 61, 651–657.
Darouiche, R.O., Mansouri, M.D., Gawande, P.V., Madhyastha, S., 2009. Antimicrobial
and antibiofilm efficacy of triclosan and DispersinB combination. J. Antimicrob.
Chemother. 64, 88–93.
Darouiche, R.O., Mansouri, M.D., Zakarevicz, D., Alsharif, A., Landon, G.C., 2007.
In vivo efficacy of antimicrobial-coated devices. J. Bone Joint Surg. Am. 89,
792–797.
De Leon, G.P., Elowe, N.H., Koteva, K.P., Valvano, M.A., Wright, G.D., 2006. An
in vitro screen of bacterial lipopolysaccharide biosynthetic enzymes identifies
an inhibitor of ADP-heptose biosynthesis. Chem. Biol. 13, 437–441.
Debarbieux, L., Leduc, D., Maura, D., Morello, E., Criscuolo, A., Grossi, O., Balloy, V.,
Touqui, L., 2010. Bacteriophages can treat and prevent Pseudomonas aeruginosa
lung infections. J. Infect. Dis. 201, 1096–1104.
Desroy, N., Moreau, F., Briet, S., Le Fralliec, G., Floquet, S., Durant, L., Vongsouthi, V., Gerusz, V., Denis, A., Escaich, S., 2009. Towards Gram-negative
antivirulence drugs: new inhibitors of HldE kinase. Bioorg. Med. Chem. 17,
1276–1289.
Doring, G., Pier, G.B., 2008. Vaccines and immunotherapy against Pseudomonas
aeruginosa. Vaccine 26, 1011–1024.
Doro, F., Liberatori, S., Rodriguez-Ortega, M.J., Rinaudo, C.D., Rosini, R., Mora, M.,
Scarselli, M., Altindis, E., D’aurizio, R., Stella, M., Margarit, I., Maione, D., Telford,
J.L., Norais, N., Grandi, G., 2009. Surfome analysis as a fast track to vaccine discovery: identification of a novel protective antigen for Group B Streptococcus
hypervirulent strain COH1. Mol. Cell. Proteom. 8, 1728–1737.
Drawz, S.M., Bonomo, R.A., 2010. Three decades of beta-lactamase inhibitors. Clin.
Microbiol. Rev. 23, 160–201.
Edwards, M.S., 2008. Group B streptococcal conjugate vaccine: a timely concept for
which the time has come. Hum. Vaccin. 4, 444–448.
Engelmayer, J., Blezinger, P., Varadhachary, A., 2008. Talactoferrin stimulates wound
healing with modulation of inflammation. J. Surg. Res. 149, 278–286.
Entenza, J.M., Loeffler, J.M., Grandgirard, D., Fischetti, V.A., Moreillon, P.,
2005. Therapeutic effects of bacteriophage Cpl-1 lysin against Streptococcus pneumoniae endocarditis in rats. Antimicrob. Agents Chemother. 49,
4789–4792.
Etz, H., Minh, D.B., Henics, T., Dryla, A., Winkler, B., Triska, C., Boyd, A.P., Sollner, J.,
Schmidt, W., Von Ahsen, U., Buschle, M., Gill, S.R., Kolonay, J., Khalak, H., Fraser,
C.M., Von Gabain, A., Nagy, E., Meinke, A., 2002. Identification of in vivo expressed
vaccine candidate antigens from Staphylococcus aureus. Proc. Natl. Acad. Sci. U.
S. A. 99, 6573–6578.
Eubanks, L.M., Hixon, M.S., Jin, W., Hong, S., Clancy, C.M., Tepp, W.H., Baldwin, M.R.,
Malizio, C.J., Goodnough, M.C., Barbieri, J.T., Johnson, E.A., Boger, D.L., Dickerson,
T.J., Janda, K.D., 2007. An in vitro and in vivo disconnect uncovered through highthroughput identification of botulinum neurotoxin A antagonists. Proc. Natl.
Acad. Sci. U. S. A. 104, 2602–2607.
Fairhead, H., 2009. SASP gene delivery: a novel antibacterial approach. Drug News
Perspect. 22, 197–203.
Falagas, M.E., Kasiakou, S.K., 2005. Colistin: the revival of polymyxins for the management of multidrug-resistant gram-negative bacterial infections. Clin. Infect.
Dis. 40, 1333–1341.
Felise, H.B., Nguyen, H.V., Pfuetzner, R.A., Barry, K.C., Jackson, S.R., Blanc, M.P., Bronstein, P.A., Kline, T., Miller, S.I., 2008. An inhibitor of gram-negative bacterial
virulence protein secretion. Cell Host Microbe 4, 325–336.
Ferreras, J.A., Ryu, J.S., Di Lello, F., Tan, D.S., Quadri, L.E., 2005. Small-molecule inhibition of siderophore biosynthesis in Mycobacterium tuberculosis and Yersinia
pestis. Nat. Chem. Biol. 1, 29–32.
Fischetti, V.A., 2010. Bacteriophage endolysins: a novel anti-infective to control
Gram-positive pathogens. Int. J. Med. Microbiol. 300, 357–362.
Fletcher, L.D., Bernfield, L., Barniak, V., Farley, J.E., Howell, A., Knauf, M., Ooi, P., Smith,
R.P., Weise, P., Wetherell, M., Xie, X., Zagursky, R., Zhang, Y., Zlotnick, G.W., 2004.
Vaccine potential of the Neisseria meningitidis 2086 lipoprotein. Infect. Immun.
72, 2088–2100.
Fritzer, A., Senn, B.M., Minh, D.B., Hanner, M., Gelbmann, D., Noiges, B., Henics,
T., Schulze, K., Guzman, C.A., Goodacre, J., Von Gabain, A., Nagy, E., Meinke,
A.L., 2010. Novel conserved group A streptococcal proteins identified by the
ANTIGENome technology as vaccine candidates for a non-M protein based vaccine. Infect. Immun. 78, 4051–4067.
Fu, W., Forster, T., Mayer, O., Curtin, J.J., Lehman, S.M., Donlan, R.M., 2010. Bacteriophage cocktail for the prevention of biofilm formation by Pseudomonas
aeruginosa on catheters in an in vitro model system. Antimicrob. Agents
Chemother. 54, 397–404.
Galan, J.E., Wolf-Watz, H., 2006. Protein delivery into eukaryotic cells by type III
secretion machines. Nature 444, 567–573.
Gauthier, A., Robertson, M.L., Lowden, M., Ibarra, J.A., Puente, J.L., Finlay, B.B., 2005.
Transcriptional inhibitor of virulence factors in enteropathogenic Escherichia
coli. Antimicrob. Agents Chemother. 49, 4101–4109.
German, N., Wei, P., Kaatz, G.W., Kerns, R.J., 2008. Synthesis and evaluation of fluoroquinolone derivatives as substrate-based inhibitors of bacterial efflux pumps.
Eur. J. Med. Chem. 43, 2453–2463.
Geske, G.D., Wezeman, R.J., Siegel, A.P., Blackwell, H.E., 2005. Small molecule
inhibitors of bacterial quorum sensing and biofilm formation. J. Am. Chem. Soc.
127, 12762–12763.
Giacometti, A., Cirioni, O., Gov, Y., Ghiselli, R., Del Prete, M.S., Mocchegiani, F., Saba,
V., Orlando, F., Scalise, G., Balaban, N., Dell’acqua, G., 2003. RNA III inhibiting peptide inhibits in vivo biofilm formation by drug-resistant Staphylococcus aureus.
Antimicrob. Agents Chemother. 47, 1979–1983.
Giefing, C., Meinke, A.L., Hanner, M., Henics, T., Bui, M.D., Gelbmann, D., Lundberg,
U., Senn, B.M., Schunn, M., Habel, A., Henriques-Normark, B., Ortqvist, A., Kalin,
M., Von Gabain, A., Nagy, E., 2008. Discovery of a novel class of highly conserved
vaccine antigens using genomic scale antigenic fingerprinting of pneumococcus
with human antibodies. J. Exp. Med. 205, 117–131.
Giuliani, M.M., Adu-Bobie, J., Comanducci, M., Arico, B., Savino, S., Santini, L., Brunelli,
B., Bambini, S., Biolchi, A., Capecchi, B., Cartocci, E., Ciucchi, L., Di Marcello, F.,
Ferlicca, F., Galli, B., Luzzi, E., Masignani, V., Serruto, D., Veggi, D., Contorni, M.,
Morandi, M., Bartalesi, A., Cinotti, V., Mannucci, D., Titta, F., Ovidi, E., Welsch,
J.A., Granoff, D., Rappuoli, R., Pizza, M., 2006. A universal vaccine for serogroup
B meningococcus. Proc. Natl. Acad. Sci. U. S. A. 103, 10834–10839.
Gorringe, A.R., Van Alphen, L., 2009. 16th International Pathogenic Neisseria Conference: recent progress towards effective meningococcal disease vaccines. Hum.
Vaccin. 5, 53–56.
Grandgirard, D., Loeffler, J.M., Fischetti, V.A., Leib, S.L., 2008. Phage lytic enzyme Cpl1 for antibacterial therapy in experimental pneumococcal meningitis. J. Infect.
Dis. 197, 1519–1522.
Granoff, D.M., 2010. Review of meningococcal group B vaccines. Clin. Infect. Dis. 50
(Suppl 2), S54–S65.
Guilherme, L., Postol, E., Freschi De Barros, S., Higa, F., Alencar, R., Lastre, M., Zayas,
C., Puschel, C.R., Silva, W.R., Sa-Rocha, L.C., Sa-Rocha, V.M., Perez, O., Kalil, J.,
2009. A vaccine against S. pyogenes: design and experimental immune response.
Methods 49, 316–321.
Gupta, R., Prasad, Y., 2011. Efficacy of polyvalent bacteriophage P-27/HP to control multidrug resistant Staphylococcus aureus associated with human infections.
Curr. Microbiol. 62, 255–260.
Guskey, M.T., Tsuji, B.T., 2010. A comparative review of the lipoglycopeptides: oritavancin, dalbavancin, and telavancin. Pharmacotherapy 30, 80–94.
Gutierrez, J.A., Crowder, T., Rinaldo-Matthis, A., Ho, M.C., Almo, S.C., Schramm, V.L.,
2009. Transition state analogs of 5’-methylthioadenosine nucleosidase disrupt
quorum sensing. Nat. Chem. Biol. 5, 251–257.
Hachem, R., Reitzel, R., Borne, A., Jiang, Y., Tinkey, P., Uthamanthil, R., Chandra, J.,
Ghannoum, M., Raad, I., 2009. Novel antiseptic urinary catheters for prevention of urinary tract infections: correlation of in vivo and in vitro test results.
Hall, A.E., Domanski, P.J., Patel, P.R., Vernachio, J.H., Syribeys, P.J., Gorovits, E.L.,
Johnson, M.A., Ross, J.M., Hutchins, J.T., Patti, J.M., 2003. Characterization of a
protective monoclonal antibody recognizing Staphylococcus aureus MSCRAMM
protein clumping factor A. Infect. Immun. 71, 6864–6870.
Hamill, T.M., Gilmore, B.F., Jones, D.S., Gorman, S.P., 2007. Strategies for the development of the urinary catheter. Expert Rev. Med. Devices 4, 215–225.
Hancock, R.E., Sahl, H.G., 2006. Antimicrobial and host-defense peptides as new antiinfective therapeutic strategies. Nat. Biotechnol. 24, 1551–1557.
Hanlon, G.W., 2007. Bacteriophages: an appraisal of their role in the treatment of
bacterial infections. Int. J. Antimicrob. Agents 30, 118–128.
Hanna, H., Bahna, P., Reitzel, R., Dvorak, T., Chaiban, G., Hachem, R., Raad, I., 2006.
Comparative in vitro efficacies and antimicrobial durabilities of novel antimicrobial central venous catheters. Antimicrob. Agents Chemother. 50, 3283–3288.
Hardes, J., Von Eiff, C., Streitbuerger, A., Balke, M., Budny, T., Henrichs, M.P.,
Hauschild, G., Ahrens, H., 2010. Reduction of periprosthetic infection with silvercoated megaprostheses in patients with bone sarcoma. J. Surg. Oncol. 101,
389–395.
Hentzer, M., Wu, H., Andersen, J.B., Riedel, K., Rasmussen, T.B., Bagge, N., Kumar, N.,
Schembri, M.A., Song, Z., Kristoffersen, P., Manefield, M., Costerton, J.W., Molin,
S., Eberl, L., Steinberg, P., Kjelleberg, S., Hoiby, N., Givskov, M., 2003. Attenuation
of Pseudomonas aeruginosa virulence by quorum sensing inhibitors. EMBO J.
22, 3803–3815.
Heo, Y.J., Lee, Y.R., Jung, H.H., Lee, J., Ko, G., Cho, Y.H., 2009. Antibacterial efficacy
of phages against Pseudomonas aeruginosa infections in mice and Drosophila
melanogaster. Antimicrob. Agents Chemother. 53, 2469–2474.
Herrmann, J.E., Wang, S., Zhang, C., Panchal, R.G., Bavari, S., Lyons, C.R., Lovchik, J.A.,
Golding, B., Shiloach, J., Lu, S., 2006. Passive immunotherapy of Bacillus anthracis
pulmonary infection in mice with antisera produced by DNA immunization.
Vaccine 24, 5872–5880.
Hockenhull, J.C., Dwan, K.M., Smith, G.W., Gamble, C.L., Boland, A., Walley, T.J., Dickson, R.C., 2009. The clinical effectiveness of central venous catheters treated with
anti-infective agents in preventing catheter-related bloodstream infections: a
systematic review. Crit. Care Med. 37, 702–712.
Horn, M.P., Zuercher, A.W., Imboden, M.A., Rudolf, M.P., Lazar, H., Wu, H., Hoiby,
N., Fas, S.C., Lang, A.B., 2010. Preclinical In Vitro and In Vivo characterization of
the fully human monoclonal IgM antibody KBPA101 specific for Pseudomonas
aeruginosa serotype IATS-O11. Antimicrob. Agents Chemother. 54, 2338–2344.
Hoshiba, H., Uchiyama, J., Kato, S., Ujihara, T., Muraoka, A., Daibata, M., Wakiguchi,
H., Matsuzaki, S., 2010. Isolation and characterization of a novel Staphylococcus
aureus bacteriophage, phiMR25, and its therapeutic potential. Arch. Virol. 155,
545–552.
Hudson, D.L., Layton, A.N., Field, T.R., Bowen, A.J., Wolf-Watz, H., Elofsson, M.,
Stevens, M.P., Galyov, E.E., 2007. Inhibition of type III secretion in Salmonella
enterica serovar Typhimurium by small-molecule inhibitors. Antimicrob. Agents
Chemother. 51, 2631–2635.
Hugonnet, J.E., Tremblay, L.W., Boshoff, H.I., Barry 3rd, C.E., Blanchard, J.S.,
2009. Meropenem-clavulanate is effective against extensively drug-resistant
Mycobacterium tuberculosis. Science 323, 1215–1218.
Hull, A.K., Criscuolo, C.J., Mett, V., Groen, H., Steeman, W., Westra, H.,
Chapman, G., Legutki, B., Baillie, L., Yusibov, V., 2005. Human-derived, plantproduced monoclonal antibody for the treatment of anthrax. Vaccine 23,
2082–2086.
Hung, D.T., Shakhnovich, E.A., Pierson, E., Mekalanos, J.J., 2005. Small-molecule
inhibitor of Vibrio cholerae virulence and intestinal colonization. Science 310,
670–674.
Ishii, Y., Eto, M., Mano, Y., Tateda, K., Yamaguchi, K., 2010. In vitro potentiation of carbapenems with ME1071, a Novel Metallo-ss-Lactamase inhibitor,
against Metallo-ss-lactamase producing Pseudomonas aeruginosa clinical isolates. Antimicrob. Agents Chemother. 54, 3625–3629.
Jabes, D., Donadio, S., 2010. Strategies for the isolation and characterization of
antibacterial lantibiotics. Methods Mol. Biol. 618, 31–45.
Jado, I., Lopez, R., Garcia, E., Fenoll, A., Casal, J., Garcia, P., 2003. Phage lytic enzymes as
therapy for antibiotic-resistant Streptococcus pneumoniae infection in a murine
sepsis model. J. Antimicrob. Chemother. 52, 967–973.
135
Jikia, D., Chkhaidze, N., Imedashvili, E., Mgaloblishvili, I., Tsitlanadze, G., Katsarava, R., Glenn Morris Jr., J., Sulakvelidze, A., 2005. The use of a novel
biodegradable preparation capable of the sustained release of bacteriophages
and ciprofloxacin, in the complex treatment of multidrug-resistant Staphylococcus aureus-infected local radiation injuries caused by exposure to Sr90. Clin.
Exp. Dermatol. 30, 23–26.
Johnson, R.P., Gyles, C.L., Huff, W.E., Ojha, S., Huff, G.R., Rath, N.C., Donoghue, A.M.,
2008. Bacteriophages for prophylaxis and therapy in cattle, poultry and pigs.
Anim. Health Res. Rev. 9, 201–215.
Kalicke, T., Schierholz, J., Schlegel, U., Frangen, T.M., Koller, M., Printzen, G., Seybold,
D., Klockner, S., Muhr, G., Arens, S., 2006. Effect on infection resistance of a local
antiseptic and antibiotic coating on osteosynthesis implants: an in vitro and
in vivo study. J. Orthop. Res. 24, 1622–1640.
Kaneko, Y., Thoendel, M., Olakanmi, O., Britigan, B.E., Singh, P.K., 2007. The transition metal gallium disrupts Pseudomonas aeruginosa iron metabolism and has
antimicrobial and antibiofilm activity. J. Clin. Invest. 117, 877–888.
Karginov, V.A., Nestorovich, E.M., Moayeri, M., Leppla, S.H., Bezrukov, S.M., 2005.
Blocking anthrax lethal toxin at the protective antigen channel by using
structure-inspired drug design. Proc. Natl. Acad. Sci. U. S. A. 102, 15075–15080.
Kaufmann, G.F., Park, J., Janda, K.D., 2008. Bacterial quorum sensing: a new target
for anti-infective immunotherapy. Expert Opin. Biol. Ther. 8, 719–724.
Kaufmann, G.F., Sartorio, R., Lee, S.H., Mee, J.M., Altobell 3rd, L.J., Kujawa, D.P., Jeffries,
E., Clapham, B., Meijler, M.M., Janda, K.D., 2006. Antibody interference with Nacyl homoserine lactone-mediated bacterial quorum sensing. J. Am. Chem. Soc.
128, 2802–2803.
Kauppi, A.M., Nordfelth, R., Uvell, H., Wolf-Watz, H., Elofsson, M., 2003. Targeting
bacterial virulence: inhibitors of type III secretion in Yersinia. Chem. Biol. 10,
241–249.
Kern, W.V., Steinke, P., Schumacher, A., Schuster, S., Von Baum, H., Bohnert,
J.A., 2006. Effect of 1-(1-naphthylmethyl)-piperazine, a novel putative efflux
pump inhibitor, on antimicrobial drug susceptibility in clinical isolates of
Escherichia coli. J. Antimicrob. Chemother. 57, 339–343.
Kimura, T., Co, M.S., Vasquez, M., Wei, S., Xu, H., Tani, S., Sakai, Y., Kawamura, T.,
Matsumoto, Y., Nakao, H., Takeda, T., 2002. Development of humanized monoclonal antibody TMA-15 which neutralizes Shiga toxin 2. Hybrid. Hybridomics
21, 161–168.
Kitov, P.I., Mulvey, G.L., Griener, T.P., Lipinski, T., Solomon, D., Paszkiewicz, E., Jacobson, J.M., Sadowska, J.M., Suzuki, M., Yamamura, K., Armstrong, G.D., Bundle,
D.R., 2008. In vivo supramolecular templating enhances the activity of multivalent ligands: a potential therapeutic against the Escherichia coli O157 AB5 toxins.
Proc. Natl. Acad. Sci. U. S. A. 105, 16837–16842.
Kitov, P.I., Sadowska, J.M., Mulvey, G., Armstrong, G.D., Ling, H., Pannu, N.S., Read,
R.J., Bundle, D.R., 2000. Shiga-like toxins are neutralized by tailored multivalent
carbohydrate ligands. Nature 403, 669–672.
Klevens, R.M., Edwards, J.R., Richards Jr., C.L., Horan, T.C., Gaynes, R.P., Pollock, D.A.,
Cardo, D.M., 2007. Estimating health care-associated infections and deaths in
U.S. hospitals, 2002. Public Health Rep. 122, 160–166.
Kotloff, K.L., Corretti, M., Palmer, K., Campbell, J.D., Reddish, M.A., Hu, M.C.,
Wasserman, S.S., Dale, J.B., 2004. Safety and immunogenicity of a recombinant
multivalent group a streptococcal vaccine in healthy adults: phase 1 trial. JAMA
292, 709–715.
Kotloff, K.L., Wasserman, S.S., Losonsky, G.A., Thomas Jr., W., Nichols, R., Edelman, R.,
Bridwell, M., Monath, T.P., 2001. Safety and immunogenicity of increasing doses
of a Clostridium difficile toxoid vaccine administered to healthy adults. Infect.
Immun. 69, 988–995.
Kudryavtsev, K.V., Bentley, M.L., Mccafferty, D.G., 2009. Probing of the cis-5-phenyl
proline scaffold as a platform for the synthesis of mechanism-based inhibitors
of the Staphylococcus aureus sortase SrtA isoform. Bioorg. Med. Chem. 17,
2886–2893.
Kumari, S., Harjai, K., Chhibber, S., 2010. Evidence to support the therapeutic
potential of bacteriophage Kpn5 in burn wound infection caused by Klebsiella
pneumoniae in BALB/c mice. J. Microbiol. Biotechnol. 20, 935–941.
Kutateladze, M., Adamia, R., 2008. Phage therapy experience at the Eliava Institute.
Med. Mal. Infect. 38, 426–430.
Laine, E., Goncalves, C., Karst, J.C., Lesnard, A., Rault, S., Tang, W.J., Malliavin, T.E.,
Ladant, D., Blondel, A., 2010. Use of allostery to identify inhibitors of calmodulininduced activation of Bacillus anthracis edema factor. Proc. Natl. Acad. Sci. U. S.
A. 107, 11277–11282.
Larsson, A., Johansson, S.M., Pinkner, J.S., Hultgren, S.J., Almqvist, F., Kihlberg, J.,
Linusson, A., 2005. Multivariate design, synthesis, and biological evaluation of
peptide inhibitors of FimC/FimH protein–protein interactions in uropathogenic
Escherichia coli. J. Med. Chem. 48, 935–945.
Larzabal, M., Mercado, E.C., Vilte, D.A., Salazar-Gonzalez, H., Cataldi, A., NavarroGarcia, F., 2010. Designed coiled-coil peptides inhibit the type three secretion
system of enteropathogenic Escherichia coli. PLoS One 5, e9046.
Lawson, M.C., Bowman, C.N., Anseth, K.S., 2007. Vancomycin derivative photopolymerized to titanium kills S. epidermidis. Clin. Orthop. Relat. Res. 461,
96–105.
Lazar, H., Horn, M.P., Zuercher, A.W., Imboden, M.A., Durrer, P., Seiberling, M., Pokorny, R., Hammer, C., Lang, A.B., 2009. Pharmacokinetics and safety profile of the
human anti P. aeruginosa serotype O11 IgM monoclonal antibody KBPA-101 in
healthy volunteers. Antimicrob. Agents Chemother 53, 3442–3446.
Lee, S., Hinz, A., Bauerle, E., Angermeyer, A., Juhaszova, K., Kaneko, Y., Singh, P.K.,
Manoil, C., 2009. Targeting a bacterial stress response to enhance antibiotic
action. Proc. Natl. Acad. Sci. U. S. A. 106, 14570–14575.
136
Leone, M., Albanese, J., Garnier, F., Sapin, C., Barrau, K., Bimar, M.C., Martin, C., 2003.
Risk factors of nosocomial catheter-associated urinary tract infection in a polyvalent intensive care unit. Intensive Care Med. 29, 1077–1080.
Leszczynski, P., Weber-Dabrowska, B., Kohutnicka, M., Luczak, M., Gorecki, A., Gorski,
A., 2006. Successful eradication of methicillin-resistant Staphylococcus aureus
(MRSA) intestinal carrier status in a healthcare worker—case report. Folia Microbiol. (Praha) 51, 236–238.
Letkiewicz, S., Miedzybrodzki, R., Fortuna, W., Weber-Dabrowska, B., Gorski, A.,
2009. Eradication of Enterococcus faecalis by phage therapy in chronic bacterial
prostatitis–case report. Folia Microbiol. (Praha) 54, 457–461.
Li, B., Pai, R., Cardinale, S.C., Butler, M.M., Peet, N.P., Moir, D.T., Bavari, S., Bowlin, T.L.,
2010. Synthesis and biological evaluation of botulinum neurotoxin a protease
inhibitors. J. Med. Chem. 53, 2264–2276.
Liu, C.I., Liu, G.Y., Song, Y., Yin, F., Hensler, M.E., Jeng, W.Y., Nizet, V., Wang, A.H., Oldfield, E., 2008. A cholesterol biosynthesis inhibitor blocks Staphylococcus aureus
virulence. Science 319, 1391–1394.
Livne, L., Kovachi, T., Sarig, H., Epand, R.F., Zaknoon, F., Epand, R.M., Mor, A.,
2009. Design and characterization of a broad -spectrum bactericidal acyl-lysyl
oligomer. Chem. Biol. 16, 1250–1258.
Loeffler, J.M., Djurkovic, S., Fischetti, V.A., 2003. Phage lytic enzyme Cpl-1 as a novel
antimicrobial for pneumococcal bacteremia. Infect. Immun. 71, 6199–6204.
Loeffler, J.M., Nelson, D., Fischetti, V.A., 2001. Rapid killing of Streptococcus pneumoniae with a bacteriophage cell wall hydrolase. Science 294, 2170–2172.
Lomovskaya, O., Warren, M.S., Lee, A., Galazzo, J., Fronko, R., Lee, M., Blais, J., Cho,
D., Chamberland, S., Renau, T., Leger, R., Hecker, S., Watkins, W., Hoshino, K.,
Ishida, H., Lee, V.J., 2001. Identification and characterization of inhibitors of
multidrug resistance efflux pumps in Pseudomonas aeruginosa: novel agents
for combination therapy. Antimicrob. Agents Chemother. 45, 105–116.
Lomovskaya, O., Zgurskaya, H.I., Totrov, M., Watkins, W.J., 2007. Waltzing transporters and ‘the dance macabre’ between humans and bacteria. Nat. Rev. Drug
Discov. 6, 56–65.
Lopez, E.L., Contrini, M.M., Glatstein, E., Gonzalez Ayala, S., Santoro, R., Allende, D.,
Ezcurra, G., Teplitz, E., Koyama, T., Matsumoto, Y., Sato, H., Sakai, K., Hoshide, S.,
Komoriya, K., Morita, T., Harning, R., Brookman, S., 2010. Safety and pharmacokinetics of urtoxazumab, a humanized monoclonal antibody, against Shiga-like
toxin 2 in healthy adults and in pediatric patients infected with Shiga-like toxinproducing Escherichia coli. Antimicrob. Agents Chemother. 54, 239–243.
Lovetri, K., Madhyastha, S., 2010. Antimicrobial and antibiofilm activity of quorum
sensing peptides and Peptide analogues against oral biofilm bacteria. Methods
Mol. Biol. 618, 383–392.
Lowy, I., Molrine, D.C., Leav, B.A., Blair, B.M., Baxter, R., Gerding, D.N., Nichol, G.,
Thomas Jr., W.D., Leney, M., Sloan, S., Hay, C.A., Ambrosino, D.M., 2010. Treatment
with monoclonal antibodies against Clostridium difficile toxins. N. Engl. J. Med.
362, 197–205.
Lu, T.K., Collins, J.J., 2009. Engineered bacteriophage targeting gene networks as
adjuvants for antibiotic therapy. Proc. Natl. Acad. Sci. U. S. A. 106, 4629–4634.
Lu, Y.J., Yadav, P., Clements, J.D., Forte, S., Srivastava, A., Thompson, C.M., Seid, R.,
Look, J., Alderson, M., Tate, A., Maisonneuve, J.F., Robertson, G., Anderson, P.W.,
Malley, R., 2010. Options for inactivation, adjuvant, and route of topical administration of a killed, unencapsulated pneumococcal whole-cell vaccine. Clin.
Vaccine Immunol. 17, 1005–1012.
Maione, D., Margarit, I., Rinaudo, C.D., Masignani, V., Mora, M., Scarselli, M., Tettelin,
H., Brettoni, C., Iacobini, E.T., Rosini, R., D’agostino, N., Miorin, L., Buccato, S.,
Mariani, M., Galli, G., Nogarotto, R., Nardi Dei, V., Vegni, F., Fraser, C., Mancuso, G.,
Teti, G., Madoff, L.C., Paoletti, L.C., Rappuoli, R., Kasper, D.L., Telford, J.L., Grandi,
G., 2005. Identification of a universal Group B streptococcus vaccine by multiple
genome screen. Science 309, 148–150.
Malley, R., 2010. Antibody and cell-mediated immunity to Streptococcus pneumoniae: implications for vaccine development. J. Mol. Med. 88, 135–142.
Mansouri, M.D., Darouiche, R.O., 2007. In vitro antimicrobial activity of Nacetylcysteine against bacteria colonising central venous catheters. Int. J.
Mansouri, M.D., Darouiche, R.O., 2008. In-vitro activity and in-vivo efficacy of
catheters impregnated with chloroxylenol and thymol against uropathogens.
Clin. Microbiol. Infect. 14, 190–192.
Manzoni, P., Rinaldi, M., Cattani, S., Pugni, L., Romeo, M.G., Messner, H., Stolfi, I.,
Decembrino, L., Laforgia, N., Vagnarelli, F., Memo, L., Bordignon, L., Saia, O.S.,
Maule, M., Gallo, E., Mostert, M., Magnani, C., Quercia, M., Bollani, L., Pedicino, R., Renzullo, L., Betta, P., Mosca, F., Ferrari, F., Magaldi, R., Stronati, M.,
Farina, D., 2009. Bovine lactoferrin supplementation for prevention of lateonset sepsis in very low-birth-weight neonates: a randomized trial. JAMA 302,
1421–1428.
Maresso, A.W., Wu, R., Kern, J.W., Zhang, R., Janik, D., Missiakas, D.M., Duban, M.E.,
Joachimiak, A., Schneewind, O., 2007. Activation of inhibitors by sortase triggers
irreversible modification of the active site. J. Biol. Chem. 282, 23129–23139.
Markoishvili, K., Tsitlanadze, G., Katsarava, R., Morris Jr., J.G., Sulakvelidze, A., 2002. A
novel sustained-release matrix based on biodegradable poly(ester amide)s and
impregnated with bacteriophages and an antibiotic shows promise in management of infected venous stasis ulcers and other poorly healing wounds. Int. J.
Dermatol. 41, 453–458.
Marza, J.A., Soothill, J.S., Boydell, P., Collyns, T.A., 2006. Multiplication of therapeutically administered bacteriophages in Pseudomonas aeruginosa infected
patients. Burns 32, 644–646.
Matsuzaki, S., Yasuda, M., Nishikawa, H., Kuroda, M., Ujihara, T., Shuin, T., Shen, Y.,
Jin, Z., Fujimoto, S., Nasimuzzaman, M.D., Wakiguchi, H., Sugihara, S., Sugiura, T.,
Koda, S., Muraoka, A., Imai, S., 2003. Experimental protection of mice against
lethal Staphylococcus aureus infection by novel bacteriophage phi MR11. J.
Infect. Dis. 187, 613–624.
Maynard, J.A., Maassen, C.B., Leppla, S.H., Brasky, K., Patterson, J.L., Iverson,
B.L., Georgiou, G., 2002. Protection against anthrax toxin by recombinant
antibody fragments correlates with antigen affinity. Nat. Biotechnol. 20,
597–601.
Mccullers, J.A., Karlstrom, A., Iverson, A.R., Loeffler, J.M., Fischetti, V.A., 2007. Novel
strategy to prevent otitis media caused by colonizing Streptococcus pneumoniae. PLoS Pathog. 3, e28.
Mcshane, H., Pathan, A.A., Sander, C.R., Keating, S.M., Gilbert, S.C., Huygen, K.,
Fletcher, H.A., Hill, A.V., 2004. Recombinant modified vaccinia virus Ankara
expressing antigen 85A boosts BCG-primed and naturally acquired antimycobacterial immunity in humans. Nat. Med. 10, 1240–1244.
Mcvay, C.S., Velasquez, M., Fralick, J.A., 2007. Phage therapy of Pseudomonas
aeruginosa infection in a mouse burn wound model. Antimicrob. Agents
Chemother. 51, 1934–1938.
Meinke, A., Henics, T., Hanner, M., Minh, D.B., Nagy, E., 2005. Antigenome technology: a novel approach for the selection of bacterial vaccine candidate antigens.
Vaccine 23, 2035–2041.
Merabishvili, M., Pirnay, J.P., Verbeken, G., Chanishvili, N., Tediashvili, M., Lashkhi, N.,
Glonti, T., Krylov, V., Mast, J., Van Parys, L., Lavigne, R., Volckaert, G., Mattheus,
W., Verween, G., De Corte, P., Rose, T., Jennes, S., Zizi, M., De Vos, D., Vaneechoutte, M., 2009. Quality-controlled small-scale production of a well-defined
bacteriophage cocktail for use in human clinical trials. PLoS One 4, e4944.
Merril, C.R., Scholl, D., Adhya, S.L., 2003. The prospect for bacteriophage therapy in
Western medicine. Nat. Rev. Drug Discov. 2, 489–497.
Min, D.H., Tang, W.J., Mrksich, M., 2004. Chemical screening by mass spectrometry
to identify inhibitors of anthrax lethal factor. Nat. Biotechnol. 22, 717–723.
Minardi, D., Ghiselli, R., Cirioni, O., Giacometti, A., Kamysz, W., Orlando, F., Silvestri,
C., Parri, G., Kamysz, E., Scalise, G., Saba, V., Giovanni, M., 2007. The antimicrobial
peptide tachyplesin III coated alone and in combination with intraperitoneal
piperacillin-tazobactam prevents ureteral stent Pseudomonas infection in a rat
subcutaneous pouch model. Peptides 28, 2293–2298.
Moayeri, M., Wiggins, J.F., Lindeman, R.E., Leppla, S.H., 2006. Cisplatin inhibition of
anthrax lethal toxin. Antimicrob. Agents Chemother. 50, 2658–2665.
Mohamed, N., Clagett, M., Li, J., Jones, S., Pincus, S., D’alia, G., Nardone, L., Babin, M.,
Spitalny, G., Casey, L., 2005. A high-affinity monoclonal antibody to anthrax protective antigen passively protects rabbits before and after aerosolized Bacillus
anthracis spore challenge. Infect. Immun. 73, 795–802.
Monteiro, D.R., Gorup, L.F., Takamiya, A.S., Ruvollo-Filho, A.C., De Camargo, E.R.,
Barbosa, D.B., 2009. The growing importance of materials that prevent microbial adhesion: antimicrobial effect of medical devices containing silver. Int. J.
Moojen, D.J., Vogely, H.C., Fleer, A., Nikkels, P.G., Higham, P.A., Verbout, A.J., Castelein,
R.M., Dhert, W.J., 2009. Prophylaxis of infection and effects on osseointegration
using a tobramycin-periapatite coating on titanium implants—an experimental
study in the rabbit. J. Orthop. Res. 27, 710–716.
Moore, A., 2003. The big and small of drug discovery. Biotech versus pharma: advantages and drawbacks in drug development. EMBO Rep. 4, 114–117.
Moreau, F., Desroy, N., Genevard, J.M., Vongsouthi, V., Gerusz, V., Le Fralliec, G.,
Oliveira, C., Floquet, S., Denis, A., Escaich, S., Wolf, K., Busemann, M., Aschenbrenner, A., 2008. Discovery of new Gram-negative antivirulence drugs: structure
and properties of novel E. coli WaaC inhibitors. Bioorg. Med. Chem. Lett. 18,
4022–4026.
Moriel, D.G., Bertoldi, I., Spagnuolo, A., Marchi, S., Rosini, R., Nesta, B., Pastorello,
I., Corea, V.A., Torricelli, G., Cartocci, E., Savino, S., Scarselli, M., Dobrindt, U.,
Hacker, J., Tettelin, H., Tallon, L.J., Sullivan, S., Wieler, L.H., Ewers, C., Pickard,
D., Dougan, G., Fontana, M.R., Rappuoli, R., Pizza, M., Serino, L., 2010. Identification of protective and broadly conserved vaccine antigens from the genome
of extraintestinal pathogenic Escherichia coli. Proc. Natl. Acad. Sci. U. S. A. 107,
9072–9077.
Morris, N.S., Stickler, D.J., 1998. Encrustation of indwelling urethral catheters by
Proteus mirabilis biofilms growing in human urine. J. Hosp. Infect. 39, 227–234.
Mourez, M., Kane, R.S., Mogridge, J., Metallo, S., Deschatelets, P., Sellman, B.R., Whitesides, G.M., Collier, R.J., 2001. Designing a polyvalent inhibitor of anthrax toxin.
Nat. Biotechnol. 19, 958–961.
Mukherjee, J., Chios, K., Fishwild, D., Hudson, D., O’donnell, S., Rich, S.M., DonohueRolfe, A., Tzipori, S., 2002. Human Stx2-specific monoclonal antibodies prevent
systemic complications of Escherichia coli O157:H7 infection. Infect. Immun. 70,
612–619.
Muschiol, S., Bailey, L., Gylfe, A., Sundin, C., Hultenby, K., Bergstrom, S., Elofsson,
M., Wolf-Watz, H., Normark, S., Henriques-Normark, B., 2006. A small-molecule
inhibitor of type III secretion inhibits different stages of the infectious cycle of
Chlamydia trachomatis. Proc. Natl. Acad. Sci. U. S. A. 103, 14566–14571.
Mygind, P.H., Fischer, R.L., Schnorr, K.M., Hansen, M.T., Sonksen, C.P., Ludvigsen, S.,
Raventos, D., Buskov, S., Christensen, B., De Maria, L., Taboureau, O., Yaver, D.,
Elvig-Jorgensen, S.G., Sorensen, M.V., Christensen, B.E., Kjaerulff, S., FrimodtMoller, N., Lehrer, R.I., Zasloff, M., Kristensen, H.H., 2005. Plectasin is a peptide
antibiotic with therapeutic potential from a saprophytic fungus. Nature 437,
975–980.
Negrea, A., Bjur, E., Ygberg, S.E., Elofsson, M., Wolf-Watz, H., Rhen, M., 2007. Salicylidene acylhydrazides that affect type III protein secretion in Salmonella enterica
serovar typhimurium. Antimicrob. Agents Chemother. 51, 2867–2876.
Nelson, D., Loomis, L., Fischetti, V.A., 2001. Prevention and elimination of upper respiratory colonization of mice by group A streptococci by using a bacteriophage
lytic enzyme. Proc. Natl. Acad. Sci. U. S. A. 98, 4107–4112.
Neville, L.F., Barnea, Y., Hammer-Munz, O., Gur, E., Kuzmenko, B., Kahel-Raifer, H.,
Eren, R., Elkeles, A., Murthy, K.G., Szabo, C., Salzman, A.L., Dagan, S., Carmeli, Y.,
Navon-Venezia, S., 2005. Antibodies raised against N’-terminal Pseudomonas
aeruginosa flagellin prevent mortality in lethal murine models of infection. Int.
J. Mol. Med. 16, 165–171.
Nilsson, E., Larsson, A., Olesen, H.V., Wejaker, P.E., Kollberg, H., 2008. Good effect
of IgY against Pseudomonas aeruginosa infections in cystic fibrosis patients.
Pediatr. Pulmonol. 43, 892–899.
Nishikawa, H., Yasuda, M., Uchiyama, J., Rashel, M., Maeda, Y., Takemura, I., Sugihara,
S., Ujihara, T., Shimizu, Y., Shuin, T., Matsuzaki, S., 2008. T-even-related bacteriophages as candidates for treatment of Escherichia coli urinary tract infections.
Arch. Virol. 153, 507–515.
Nishikawa, K., Matsuoka, K., Kita, E., Okabe, N., Mizuguchi, M., Hino, K., Miyazawa, S.,
Yamasaki, C., Aoki, J., Takashima, S., Yamakawa, Y., Nishijima, M., Terunuma, D.,
Kuzuhara, H., Natori, Y., 2002. A therapeutic agent with oriented carbohydrates
for treatment of infections by Shiga toxin-producing Escherichia coli O157:H7.
O’flaherty, S., Ross, R.P., Coffey, A., 2009. Bacteriophage and their lysins for elimination of infectious bacteria. FEMS Microbiol. Rev. 33, 801–819.
Oh, K.B., Kim, S.H., Lee, J., Cho, W.J., Lee, T., Kim, S., 2004. Discovery of diarylacrylonitriles as a novel series of small molecule sortase A inhibitors. J. Med. Chem.
47, 2418–2421.
Ostergaard, C., Sandvang, D., Frimodt-Moller, N., Kristensen, H.H., 2009. High cerebrospinal fluid (CSF) penetration and potent bactericidal activity in CSF of
NZ2114, a novel plectasin variant, during experimental pneumococcal meningitis. Antimicrob. Agents Chemother. 53, 1581–1585.
Pan, N.J., Brady, M.J., Leong, J.M., Goguen, J.D., 2009. Targeting type III secretion in
Yersinia pestis. Antimicrob. Agents Chemother. 53, 385–392.
Panchal, R.G., Hermone, A.R., Nguyen, T.L., Wong, T.Y., Schwarzenbacher, R., Schmidt,
J., Lane, D., Mcgrath, C., Turk, B.E., Burnett, J., Aman, M.J., Little, S., Sausville,
E.A., Zaharevitz, D.W., Cantley, L.C., Liddington, R.C., Gussio, R., Bavari, S., 2004.
Identification of small molecule inhibitors of anthrax lethal factor. Nat. Struct.
Mol. Biol. 11, 67–72.
Pang, Y.P., Davis, J., Wang, S., Park, J.G., Nambiar, M.P., Schmidt, J.J., Millard, C.B.,
2010. Small molecules showing significant protection of mice against botulinum
neurotoxin serotype A. PLoS One 5, e10129.
Pannek, S., Higgins, P.G., Steinke, P., Jonas, D., Akova, M., Bohnert, J.A., Seifert,
H., Kern, W.V., 2006. Multidrug efflux inhibition in Acinetobacter baumannii:
comparison between 1-(1-naphthylmethyl)-piperazine and phenyl-argininebeta-naphthylamide. J. Antimicrob. Chemother. 57, 970–974.
Park, J., Jagasia, R., Kaufmann, G.F., Mathison, J.C., Ruiz, D.I., Moss, J.A., Meijler, M.M.,
Ulevitch, R.J., Janda, K.D., 2007. Infection control by antibody disruption of bacterial quorum sensing signaling. Chem. Biol. 14, 1119–1127.
Paton, A.W., Morona, R., Paton, J.C., 2000. A new biological agent for treatment of
Shiga toxigenic Escherichia coli infections and dysentery in humans. Nat. Med.
6, 265–270.
Pattanaik, P., Bethel, C.R., Hujer, A.M., Hujer, K.M., Distler, A.M., Taracila, M., Anderson, V.E., Fritsche, T.R., Jones, R.N., Pagadala, S.R., Van Den Akker, F., Buynak, J.D.,
Bonomo, R.A., 2009. Strategic design of an effective beta-lactamase inhibitor:
LN-1-255, a 6-alkylidene-2’-substituted penicillin sulfone. J. Biol. Chem. 284,
945–953.
Paukner, S., Hesse, L., Prezelj, A., Solmajer, T., Urleb, U., 2009. In vitro activity
of LK-157, a novel tricyclic carbapenem as broad-spectrum {beta}-lactamase
inhibitor. Antimicrob. Agents Chemother. 53, 505–511.
Payne, D.J., Gwynn, M.N., Holmes, D.J., Pompliano, D.L., 2007. Drugs for bad bugs:
confronting the challenges of antibacterial discovery. Nat. Rev. Drug Discov. 6,
29–40.
Petersen, P.J., Jones, C.H., Venkatesan, A.M., Bradford, P.A., 2009. Efficacy of
piperacillin combined with the Penem beta-lactamase inhibitor BLI-489 in
murine models of systemic infection. Antimicrob. Agents Chemother. 53,
1698–1700.
Peterson, J.W., Comer, J.E., Noffsinger, D.M., Wenglikowski, A., Walberg, K.G., Chatuev, B.M., Chopra, A.K., Stanberry, L.R., Kang, A.S., Scholz, W.W., Sircar, J., 2006.
Human monoclonal anti-protective antigen antibody completely protects rabbits and is synergistic with ciprofloxacin in protecting mice and guinea pigs
against inhalation anthrax. Infect. Immun. 74, 1016–1024.
Pier, G.B., Boyer, D., Preston, M., Coleman, F.T., Llosa, N., Mueschenborn-Koglin,
S., Theilacker, C., Goldenberg, H., Uchin, J., Priebe, G.P., Grout, M., Posner, M.,
Cavacini, L., 2004. Human monoclonal antibodies to Pseudomonas aeruginosa
alginate that protect against infection by both mucoid and nonmucoid strains.
J. Immunol. 173, 5671–5678.
Pinkner, J.S., Remaut, H., Buelens, F., Miller, E., Aberg, V., Pemberton, N., Hedenstrom,
M., Larsson, A., Seed, P., Waksman, G., Hultgren, S.J., Almqvist, F., 2006. Rationally
designed small compounds inhibit pilus biogenesis in uropathogenic bacteria.
Pizza, M., Scarlato, V., Masignani, V., Giuliani, M.M., Arico, B., Comanducci, M., Jennings, G.T., Baldi, L., Bartolini, E., Capecchi, B., Galeotti, C.L., Luzzi, E., Manetti, R.,
Marchetti, E., Mora, M., Nuti, S., Ratti, G., Santini, L., Savino, S., Scarselli, M., Storni,
E., Zuo, P., Broeker, M., Hundt, E., Knapp, B., Blair, E., Mason, T., Tettelin, H., Hood,
D.W., Jeffries, A.C., Saunders, N.J., Granoff, D.M., Venter, J.C., Moxon, E.R., Grandi,
G., Rappuoli, R., 2000. Identification of vaccine candidates against serogroup B
meningococcus by whole-genome sequencing. Science 287, 1816–1820.
Politano, A.D., Sawyer, R.G., 2010. NXL-103, a combination of flopristin and
linopristin, for the potential treatment of bacterial infections including
community-acquired pneumonia and MRSA. Curr. Opin. Investig. Drugs 11,
225–236.
137
Prasad, A., Cevallos, M.E., Riosa, S., Darouiche, R.O., Trautner, B.W., 2009. A bacterial
interference strategy for prevention of UTI in persons practicing intermittent
catheterization. Spinal Cord 47, 565–569.
Radin, S., Campbell, J.T., Ducheyne, P., Cuckler, J.M., 1997. Calcium phosphate ceramic
coatings as carriers of vancomycin. Biomaterials 18, 777–782.
Radzishevsky, I.S., Rotem, S., Bourdetsky, D., Navon-Venezia, S., Carmeli, Y., Mor,
A., 2007. Improved antimicrobial peptides based on acyl-lysine oligomers. Nat.
Biotechnol. 25, 657–659.
Ragle, B.E., Bubeck Wardenburg, J., 2009. Anti-alpha-hemolysin monoclonal antibodies mediate protection against Staphylococcus aureus pneumonia. Infect.
Immun. 77, 2712–2718.
Ragle, B.E., Karginov, V.A., Bubeck Wardenburg, J., 2010. Prevention and treatment of
Staphylococcus aureus pneumonia with a beta-cyclodextrin derivative. Antimicrob. Agents Chemother. 54, 298–304.
Rappuoli, R., 2000. Reverse vaccinology. Curr. Opin. Microbiol. 3, 445–450.
Rashel, M., Uchiyama, J., Ujihara, T., Uehara, Y., Kuramoto, S., Sugihara, S., Yagyu,
K., Muraoka, A., Sugai, M., Hiramatsu, K., Honke, K., Matsuzaki, S., 2007. Efficient
elimination of multidrug-resistant Staphylococcus aureus by cloned lysin derived
from bacteriophage phi MR11. J. Infect. Dis. 196, 1237–1247.
Rasko, D.A., Moreira, C.G., Li De, R., Reading, N.C., Ritchie, J.M., Waldor, M.K., Williams,
N., Taussig, R., Wei, S., Roth, M., Hughes, D.T., Huntley, J.F., Fina, M.W., Falck,
J.R., Sperandio, V., 2008. Targeting QseC signaling and virulence for antibiotic
development. Science 321, 1078–1080.
Reichert, J.M., Rosensweig, C.J., Faden, L.B., Dewitz, M.C., 2005. Monoclonal antibody
successes in the clinic. Nat. Biotechnol. 23, 1073–1078.
Rhoads, D.D., Wolcott, R.D., Kuskowski, M.A., Wolcott, B.M., Ward, L.S., Sulakvelidze,
A., 2009. Bacteriophage therapy of venous leg ulcers in humans: results of a
phase I safety trial. J. Wound Care 18, 237–243.
Riley, M.A., Wertz, J.E., 2002. Bacteriocins: evolution, ecology, and application. Annu.
Rev. Microbiol. 56, 117–137.
Rodriguez-Ortega, M.J., Norais, N., Bensi, G., Liberatori, S., Capo, S., Mora, M., Scarselli,
M., Doro, F., Ferrari, G., Garaguso, I., Maggi, T., Neumann, A., Covre, A., Telford,
J.L., Grandi, G., 2006. Characterization and identification of vaccine candidate
proteins through analysis of the group A Streptococcus surface proteome. Nat.
Biotechnol. 24, 191–197.
Rotem, S., Radzishevsky, I.S., Bourdetsky, D., Navon-Venezia, S., Carmeli, Y., Mor,
A., 2008. Analogous oligo-acyl-lysines with distinct antibacterial mechanisms.
FASEB J. 22, 2652–2661.
Roxas-Duncan, V., Enyedy, I., Montgomery, V.A., Eccard, V.S., Carrington, M.A., Lai,
H., Gul, N., Yang, D.C., Smith, L.A., 2009. Identification and biochemical characterization of small-molecule inhibitors of Clostridium botulinum neurotoxin
serotype A. Antimicrob. Agents Chemother. 53, 3478–3486.
Sangwan, P.L., Koul, J.L., Koul, S., Reddy, M.V., Thota, N., Khan, I.A., Kumar, A., Kalia,
N.P., Qazi, G.N., 2008. Piperine analogs as potent Staphylococcus aureus NorA
efflux pump inhibitors. Bioorg. Med. Chem. 16, 9847–9857.
Sarig, H., Livne, L., Held-Kuznetsov, V., Zaknoon, F., Ivankin, A., Gidalevitz, D., Mor, A.,
2010. A miniature mimic of host defense peptides with systemic antibacterial
efficacy. FASEB J. 24, 1904–1913.
Schaffer, A.C., Lee, J.C., 2008. Vaccination and passive immunisation against Staphylococcus aureus. Int. J. Antimicrob. Agents 32 (Suppl. 1), S71–S78.
Schmidt, J.J., Stafford, R.G., 2002. A high-affinity competitive inhibitor of type A
botulinum neurotoxin protease activity. FEBS Lett. 532, 423–426.
Schmidtchen, A., Pasupuleti, M., Morgelin, M., Davoudi, M., Alenfall, J., Chalupka, A.,
Malmsten, M., 2009. Boosting antimicrobial peptides by hydrophobic oligopeptide end tags. J. Biol. Chem. 284, 17584–17594.
Schneider, T., Kruse, T., Wimmer, R., Wiedemann, I., Sass, V., Pag, U., Jansen, A.,
Nielsen, A.K., Mygind, P.H., Raventos, D.S., Neve, S., Ravn, B., Bonvin, A.M., De
Maria, L., Andersen, A.S., Gammelgaard, L.K., Sahl, H.G., Kristensen, H.H., 2010.
Plectasin, a fungal defensin, targets the bacterial cell wall precursor Lipid II.
Science 328, 1168–1172.
Schuch, R., Nelson, D., Fischetti, V.A., 2002. A bacteriolytic agent that detects and
kills Bacillus anthracis. Nature 418, 884–889.
Schumacher, A., Steinke, P., Bohnert, J.A., Akova, M., Jonas, D., Kern, W.V., 2006. Effect
of 1-(1-naphthylmethyl)-piperazine, a novel putative efflux pump inhibitor, on
antimicrobial drug susceptibility in clinical isolates of Enterobacteriaceae other
than Escherichia coli. J. Antimicrob. Chemother. 57, 344–348.
Schumm, K., Lam, T.B., 2008. Types of urethral catheters for management of shortterm voiding problems in hospitalised adults. Cochrane Database Syst. Rev.,
CD004013.
Scott, M.G., Dullaghan, E., Mookherjee, N., Glavas, N., Waldbrook, M., Thompson,
A., Wang, A., Lee, K., Doria, S., Hamill, P., Yu, J.J., Li, Y., Donini, O., Guarna,
M.M., Finlay, B.B., North, J.R., Hancock, R.E., 2007. An anti-infective peptide
that selectively modulates the innate immune response. Nat. Biotechnol. 25,
465–472.
Shoop, W.L., Xiong, Y., Wiltsie, J., Woods, A., Guo, J., Pivnichny, J.V., Felcetto, T.,
Michael, B.F., Bansal, A., Cummings, R.T., Cunningham, B.R., Friedlander, A.M.,
Douglas, C.M., Patel, S.B., Wisniewski, D., Scapin, G., Salowe, S.P., Zaller, D.M.,
Chapman, K.T., Scolnick, E.M., Schmatz, D.M., Bartizal, K., Maccoss, M., Hermes,
J.D., 2005. Anthrax lethal factor inhibition. Proc. Natl. Acad. Sci. U. S. A. 102,
7958–7963.
Silhar, P., Capkova, K., Salzameda, N.T., Barbieri, J.T., Hixon, M.S., Janda, K.D.,
2010. Botulinum neurotoxin A protease: discovery of natural product exosite
inhibitors. J. Am. Chem. Soc. 132, 2868–2869.
Simpson, I.N., Urch, C.J., Hagen, G., Albrecht, R., Sprinkart, B., Pfaendler, H.R., 2003.
Synthesis and biological activity of AM-112 and related oxapenem analogues. J.
Antibiot. (Tokyo) 56, 838–847.
138
Staats, H.F., Alam, S.M., Scearce, R.M., Kirwan, S.M., Zhang, J.X., Gwinn, W.M., Haynes,
B.F., 2007. In vitro and in vivo characterization of anthrax anti-protective antigen
and anti-lethal factor monoclonal antibodies after passive transfer in a mouse
lethal toxin challenge model to define correlates of immunity. Infect. Immun.
75, 5443–5452.
Stachyra, T., Levasseur, P., Pechereau, M.C., Girard, A.M., Claudon, M.,
Miossec, C., Black, M.T., 2009. In vitro activity of the {beta}-lactamase
inhibitor NXL104 against KPC-2 carbapenemase and Enterobacteriaceae expressing KPC carbapenemases. J. Antimicrob. Chemother. 64,
326–329.
Stickler, D., 2008. Comment re: Types of urethral catheters for management of
short-term voiding problems in hospitalized adults. Neurourol. Urodyn. 27,
748.
Subramanian, G.M., Cronin, P.W., Poley, G., Weinstein, A., Stoughton, S.M., Zhong,
J., Ou, Y., Zmuda, J.F., Osborn, B.L., Freimuth, W.W., 2005. A phase 1 study of
PAmAb, a fully human monoclonal antibody against Bacillus anthracis protective
antigen, in healthy volunteers. Clin. Infect. Dis. 41, 12–20.
Suree, N., Yi, S.W., Thieu, W., Marohn, M., Damoiseaux, R., Chan, A., Jung,
M.E., Clubb, R.T., 2009. Discovery and structure-activity relationship analysis of Staphylococcus aureus sortase A inhibitors. Bioorg. Med. Chem. 17,
7174–7185.
Svensson, A., Larsson, A., Emtenas, H., Hedenstrom, M., Fex, T., Hultgren, S.J., Pinkner,
J.S., Almqvist, F., Kihlberg, J., 2001. Design and evaluation of pilicides: potential novel antibacterial agents directed against uropathogenic Escherichia coli.
Chembiochem. 2, 915–918.
Tanji, Y., Shimada, T., Fukudomi, H., Miyanaga, K., Nakai, Y., Unno, H., 2005.
Therapeutic use of phage cocktail for controlling Escherichia coli O157:H7 in
gastrointestinal tract of mice. J. Biosci. Bioeng. 100, 280–287.
Tilahun, M.E., Rajagopalan, G., Shah-Mahoney, N., Lawlor, R.G., Tilahun, A.Y., Xie, C.,
Natarajan, K., Margulies, D.H., Ratner, D.I., Osborne, B.A., Goldsby, R.A., 2010.
Potent neutralization of staphylococcal enterotoxin B by synergistic action of
chimeric antibodies. Infect. Immun. 78, 2801–2811.
Tonello, F., Seveso, M., Marin, O., Mock, M., Montecucco, C., 2002. Screening
inhibitors of anthrax lethal factor. Nature 418, 386.
Trachtman, H., Cnaan, A., Christen, E., Gibbs, K., Zhao, S., Acheson, D.W., Weiss, R.,
Kaskel, F.J., Spitzer, A., Hirschman, G.H., 2003. Effect of an oral Shiga toxinbinding agent on diarrhea-associated hemolytic uremic syndrome in children:
a randomized controlled trial. JAMA 290, 1337–1344.
Trautner, B.W., Hull, R.A., Darouiche, R.O., 2005. Colicins prevent colonization of
urinary catheters. J. Antimicrob. Chemother. 56, 413–415.
Trautner, B.W., Hull, R.A., Thornby, J.I., Darouiche, R.O., 2007. Coating urinary catheters with an avirulent strain of Escherichia coli as a means to
establish asymptomatic colonization. Infect. Control Hosp. Epidemiol. 28,
92–94.
Turk, B.E., Wong, T.Y., Schwarzenbacher, R., Jarrell, E.T., Leppla, S.H., Collier, R.J.,
Liddington, R.C., Cantley, L.C., 2004. The structural basis for substrate and
inhibitor selectivity of the anthrax lethal factor. Nat. Struct. Mol. Biol. 11,
60–66.
Uchiyama, J., Rashel, M., Takemura, I., Wakiguchi, H., Matsuzaki, S., 2008. In silico
and in vivo evaluation of bacteriophage phiEF24C, a candidate for treatment of
Enterococcus faecalis infections. Appl. Environ. Microbiol. 74, 4149–4163.
Walsh, S., Kokai-Kun, J., Shah, A., Mond, J., 2004. Extended nasal residence time
of lysostaphin and an anti-staphylococcal monoclonal antibody by delivery in
semisolid or polymeric carriers. Pharm. Res. 21, 1770–1775.
Walz, J.M., Avelar, R.L., Longtine, K.J., Mermel, L.A., Heard, S.O., 2010. Anti-infective
external coating of central venous catheters: A randomized, noninferiority trial
comparing 5-fluorouracil with chlorhexidine/silver sulfadiazine in preventing
catheter colonization. Crit. Care. Med 38, 2095–2102.
Van Den Dobbelsteen, G.P., Van Dijken, H.H., Pillai, S., Van Alphen, L., 2007. Immunogenicity of a combination vaccine containing pneumococcal conjugates and
meningococcal PorA OMVs. Vaccine 25, 2491–2496.
Wang, H., Huang, T., Jing, J., Jin, J., Wang, P., Yang, M., Cui, W., Zheng, Y., Shen, H.,
2010. Effectiveness of different central venous catheters for catheter-related
infections: a network meta-analysis. J. Hosp. Infect. 76, 1–11.
Wang, J., Hu, B., Xu, M., Yan, Q., Liu, S., Zhu, X., Sun, Z., Reed, E., Ding, L., Gong, J., Li,
Q.Q., Hu, J., 2006a. Use of bacteriophage in the treatment of experimental animal
bacteremia from imipenem-resistant Pseudomonas aeruginosa. Int. J. Mol. Med.
17, 309–317.
Wang, J., Hu, B., Xu, M., Yan, Q., Liu, S., Zhu, X., Sun, Z., Tao, D., Ding, L., Reed, E., Gong,
J., Li, Q.Q., Hu, J., 2006b. Therapeutic effectiveness of bacteriophages in the rescue of mice with extended spectrum beta-lactamase-producing Escherichia coli
bacteremia. Int. J. Mol. Med. 17, 347–355.
Watanabe-Takahashi, M., Sato, T., Dohi, T., Noguchi, N., Kano, F., Murata, M., Hamabata, T., Natori, Y., Nishikawa, K., 2010. An orally applicable Shiga toxin
neutralizer functions in the intestine to inhibit the intracellular transport of
the toxin. Infect. Immun. 78, 177–183.
Watanabe, R., Matsumoto, T., Sano, G., Ishii, Y., Tateda, K., Sumiyama, Y., Uchiyama, J.,
Sakurai, S., Matsuzaki, S., Imai, S., Yamaguchi, K., 2007. Efficacy of bacteriophage
therapy against gut-derived sepsis caused by Pseudomonas aeruginosa in mice.
Weber-Dabrowska, B., Mulczyk, M., Gorski, A., 2003. Bacteriophages as an efficient therapy for antibiotic-resistant septicemia in man. Transplant. Proc. 35,
1385–1386.
Veenendaal, A.K., Sundin, C., Blocker, A.J., 2009. Small-molecule type III secretion
system inhibitors block assembly of the Shigella type III secreton. J. Bacteriol.
191, 563–570.
Weinrich Olsen, A., Van Pinxteren, L.A., Meng Okkels, L., Birk Rasmussen, P.,
Andersen, P., 2001. Protection of mice with a tuberculosis subunit vaccine
based on a fusion protein of antigen 85b and esat-6. Infect. Immun. 69,
2773–2778.
Weisman, L.E., Thackray, H.M., Garcia-Prats, J.A., Nesin, M., Schneider, J.H., Fretz, J.,
Kokai-Kun, J.F., Mond, J.J., Kramer, W.G., Fischer, G.W., 2009. Phase 1/2 doubleblind, placebo-controlled, dose escalation, safety, and pharmacokinetic study of
pagibaximab (BSYX-A110), an antistaphylococcal monoclonal antibody for the
prevention of staphylococcal bloodstream infections, in very-low-birth-weight
neonates. Antimicrob. Agents Chemother. 53, 2879–2886.
Velden, W.J., Van Iersel, T.M., Blijlevens, N.M., Donnelly, J.P., 2009. Safety and tolerability of the antimicrobial peptide human lactoferrin 1-11 (hLF1-11). BMC Med.
7, 44.
Wellens, A., Garofalo, C., Nguyen, H., Van Gerven, N., Slattegard, R., Hernalsteens, J.P.,
Wyns, L., Oscarson, S., De Greve, H., Hultgren, S., Bouckaert, J., 2008. Intervening
with urinary tract infections using anti-adhesives based on the crystal structure
of the FimH-oligomannose-3 complex. PLoS One 3, e2040.
Verbeken, G., De Vos, D., Vaneechoutte, M., Merabishvili, M., Zizi, M., Pirnay, J.P.,
2007. European regulatory conundrum of phage therapy. Future Microbiol. 2,
485–491.
Vester, H., Wildemann, B., Schmidmaier, G., Stockle, U., Lucke, M., 2010. Gentamycin
delivered from a PDLLA coating of metallic implants In vivo and in vitro characterisation for local prophylaxis of implant-related osteomyelitis. Injury 41,
1053–1059.
Vidaillac, C., Guillon, J., Arpin, C., Forfar-Bares, I., Ba, B.B., Grellet, J., Moreau, S., Caignard, D.H., Jarry, C., Quentin, C., 2007. Synthesis of omeprazole analogues and
evaluation of these as potential inhibitors of the multidrug efflux pump NorA of
Staphylococcus aureus. Antimicrob. Agents Chemother. 51, 831–838.
Wild, M.A., Xin, H., Maruyama, T., Nolan, M.J., Calveley, P.M., Malone, J.D., Wallace, M.R., Bowdish, K.S., 2003. Human antibodies from immunized donors are
protective against anthrax toxin in vivo. Nat. Biotechnol. 21, 1305–1306.
Wills, Q.F., Kerrigan, C., Soothill, J.S., 2005. Experimental bacteriophage protection
against Staphylococcus aureus abscesses in a rabbit model. Antimicrob. Agents
Chemother. 49, 1220–1221.
Vinodkumar, C.S., Kalsurmath, S., Neelagund, Y.F., 2008. Utility of lytic bacteriophage
in the treatment of multidrug-resistant Pseudomonas aeruginosa septicemia in
mice. Indian J. Pathol. Microbiol. 51, 360–366.
Vinodkumar, C.S., Neelagund, Y.F., Kalsurmath, S., 2005. Bacteriophage in the treatment of experimental septicemic mice from a clinical isolate of multidrug
resistant Klebsiella pneumoniae. J. Commun. Dis. 37, 18–29.
Vitale, L., Blanset, D., Lowy, I., O’neill, T., Goldstein, J., Little, S.F., Andrews, G.P.,
Dorough, G., Taylor, R.K., Keler, T., 2006. Prophylaxis and therapy of inhalational anthrax by a novel monoclonal antibody to protective antigen that mimics
vaccine-induced immunity. Infect. Immun. 74, 5840–5847.
Witzenrath, M., Schmeck, B., Doehn, J.M., Tschernig, T., Zahlten, J., Loeffler, J.M., Zemlin, M., Muller, H., Gutbier, B., Schutte, H., Hippenstiel, S., Fischetti, V.A., Suttorp,
N., Rosseau, S., 2009. Systemic use of the endolysin Cpl-1 rescues mice with fatal
pneumococcal pneumonia. Crit. Care. Med. 37, 642–649.
Wolf, K., Betts, H.J., Chellas-Gery, B., Hower, S., Linton, C.N., Fields, K.A., 2006. Treatment of Chlamydia trachomatis with a small molecule inhibitor of the Yersinia
type III secretion system disrupts progression of the chlamydial developmental
cycle. Mol. Microbiol. 61, 1543–1555.
Von Eschen, K., Morrison, R., Braun, M., Ofori-Anyinam, O., De Kock, E., Pavithran,
P., Koutsoukos, M., Moris, P., Cain, D., Dubois, M.C., Cohen, J., Ballou, W.R., 2009.
The candidate tuberculosis vaccine Mtb72F/AS02A: Tolerability and immunogenicity in humans. Hum. Vaccin. 5, 475–482.
Woosley, L.N., Castanheira, M., Jones, R.N., 2010. CEM-101 activity against Grampositive organisms. Antimicrob. Agents Chemother. 54, 2182–2187.
Wright, A., Hawkins, C.H., Anggard, E.E., Harper, D.R., 2009. A controlled clinical trial of a therapeutic bacteriophage preparation in chronic otitis due to
antibiotic-resistant Pseudomonas aeruginosa; a preliminary report of efficacy.
Clin. Otolaryngol. 34, 349–357.
Xiong, Y., Wiltsie, J., Woods, A., Guo, J., Pivnichny, J.V., Tang, W., Bansal, A., Cummings,
R.T., Cunningham, B.R., Friedlander, A.M., Douglas, C.M., Salowe, S.P., Zaller, D.M.,
Scolnick, E.M., Schmatz, D.M., Bartizal, K., Hermes, J.D., Maccoss, M., Chapman,
K.T., 2006. The discovery of a potent and selective lethal factor inhibitor for
adjunct therapy of anthrax infection. Bioorg. Med. Chem. Lett. 16, 964–968.
Yoong, P., Schuch, R., Nelson, D., Fischetti, V.A., 2004. Identification of a broadly active
phage lytic enzyme with lethal activity against antibiotic-resistant Enterococcus
faecalis and Enterococcus faecium. J. Bacteriol. 186, 4808–4812.
Yoong, P., Schuch, R., Nelson, D., Fischetti, V.A., 2006. PlyPH, a bacteriolytic enzyme
with a broad pH range of activity and lytic action against Bacillus anthracis. J.
Bacteriol. 188, 2711–2714.
Yoshida, K., Nakayama, K., Ohtsuka, M., Kuru, N., Yokomizo, Y., Sakamoto, A., Takemura, M., Hoshino, K., Kanda, H., Nitanai, H., Namba, K., Yoshida, K., Imamura,
Y., Zhang, J.Z., Lee, V.J., Watkins, W.J., 2007. MexAB-OprM specific efflux pump
inhibitors in Pseudomonas aeruginosa, Part 7: highly soluble and in vivo active
quaternary ammonium analogue D13-9001, a potential preclinical candidate.
Bioorg. Med. Chem. 15, 7087–7097.
Zasloff, M., 2002. Antimicrobial peptides of multicellular organisms. Nature 415,
389–395.
Zhang, L., Falla, T.J., 2010. Potential therapeutic application of host defense peptides.
Methods Mol. Biol. 618, 303–327.
Zhao, P., Liang, X., Kalbfleisch, J., Koo, H.M., Cao, B., 2003. Neutralizing monoclonal
antibody against anthrax lethal factor inhibits intoxication in a mouse model.
Hum. Antibodies 12, 129–135.
Zhou, B., Carney, C., Janda, K.D., 2008. Selection and characterization of human antibodies neutralizing Bacillus anthracis toxin. Bioorg. Med. Chem. 16, 1903–1913.
Zimecki, M., Artym, J., Kocieba, M., Weber-Dabrowska, B., Borysowski, J., Gorski, A.,
2009. Effects of prophylactic administration of bacteriophages to immunosuppressed mice infected with Staphylococcus aureus. BMC Microbiol. 9, 169.
Zimecki, M., Artym, J., Kocieba, M., Weber-Dabrowska, B., Borysowski, J., Gorski, A.,
2010. Prophylactic effect of bacteriophages on mice subjected to chemotherapy-
139
induced immunosuppression and bone marrow transplant upon infection with
Staphylococcus aureus. Med. Microbiol. Immunol. 199, 71–79.
Zollinger, W.D., Donets, M.A., Schmiel, D.H., Pinto, V.B., Labrie 3rd, J.E., Moran,
E.E., Brandt, B.L., Ionin, B., Marques, R., Wu, M., Chen, P., Stoddard, M.B.,
Keiser, P.B., 2010. Design and evaluation in mice of a broadly protective
meningococcal group B native outer membrane vesicle vaccine. Vaccine 28,
5057–5067.

Drug Resistance Updates Fighting bacterial infections—Future treatment options Jenny Fernebro 夽

Transcription

Similar documents

iProtect Leaflet

ACVR Abstracts Flyer

Vaxtracker for National Vaccine Safety Surveillance

May 2013

College/Employment Waiver Form - Michigan Opposing Mandatory

AmVac AG Strong Team and Renowned Advisors INVESTMENT HIGHLIGHTS Portfolio with exceptional potential

Health History Questionnaire

Imrex Phenrex

Demystifying Blood Groups

Pegboard promo website

Aztreonam treatment of gram-negative septicemia.

R E V I E W A R T I... Quinolones in 2005: an update